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Abstract
Background: C-reactive protein (CRP) is a well-known marker for inflammation.
Recent studies have demonstrated that increases in CRP concentrations are associated
with future coronary events in apparently healthy men and women. The requirement for
assays, capable of testing CRP concentrations within the range 1-lOmg/l, is therefore
great.
Methods: Two CRP assays were developed. The Sensitive assay is capable of
measuring CRP concentrations as low as lmg/1 for use as a potential cardiac marker
test. The Normal assay can measure concentrations from 5-400mg/l for establishing
levels of inflammation. Both assays developed are latex particle enhanced
immunoturbidimetric assays designed for use on the Olympus AU2700/640/400 series
of analytical analysers. The anti-CRP antibodies were chemically bound to latex
microparticles of different sizes and surface chemistries. Various antibodies, binding
techniques, buffer composition and blocking proteins were tested. The performance of
the final assays was then established. The assay was tested for its linearity, precision
and LDL. Bilirubin, haemolytic and lipaemic interference studies were assessed. A
method comparison was also performed between the newly developed CRP assay and a
commercial CRP assay.
Results: The Sensitive assay developed is linear from l-13mg/l with precision of <2%
across this range. The LDL was O.Mmg/l. Interference from bilirubin was negligible.
Interference greater than 10% was observed with lipaemic samples > 400mg/dl and
haemolytic samples > 150mg/dl. Good correlation was observed between the new
sensitive assay and the commercial assay tested at CRP concentrations above 2.5mg/l.
There is a positive bias with patient samples measured below this concentration. The
Normal assay developed is linear from L66-480mg/l with precision of <1% above
lOmg/1. Precision at concentration of 5mg/l is <8%. The LDL is L66mg/1. Interference
from bilirubin, intralipid and haemolysate was negligible. Good correlation was
observed between the new normal assay and the commercial assay tested at CRP
concentrations above approximately lOmg/1. In samples below this concentration
significant matrix effects were observed.
Conclusions: Both assays developed are capable of measuring CRP in the required
ranges. Comparison with commercial assays is favourable. The Sensitive assay has a
positive bias below 2.5mg/l compared with the commercial assay. The assay if
unchanged would thus produce false positive results by reporting higher CRP
concentrations than actually present in patients below this concentration. These assays
nonetheless may be able to predict short and long term cardiovascular outcomes and
may have a role alongside cholesterol testing in Coronary Heart Disease screening
programmes.

1.0

Introduction

Coronary Heart Disease (CHD), which was previously thought of as a disease of lipid
deposition, is the major cause of death in the developed world. Cholesterol screening is
a well-known tool for identifying those at high risk of developing CHD. Although
useful, this approach fails to highlight almost half of the 1.3 million people who
develop MI (Myocardial Infarction) in the US each year (Rifai 2001). These people
have either normal or only moderately high cholesterol concentrations. Only 50% of
those in the Framingham Heart Study who sustained a MI had increased total
cholesterol (TC) concentrations (Kannel 1995). As a result of efforts to understand
these findings CHD is now viewed as a process involving multiple elements in which
chronic inflammation plays a significant role (Ferranti 2002). In recent years there have
been many clinical trials establishing the possibility for utilising CRP, a well-known
marker for inflammation, in the prognosis of CHD. CRP’s ability to predict future first
time coronary events has also been investigated. CRP concentration is found to be
increased in serum of patients with MI (Lombardi 2005).

Synthesised in the liver in response to the release of inflammatory cytokines, C reactive protein (CRP) is an acute-phase inflammatory biomarker (de Maat 2004).

Tillet and Francis initially discovered CRP in the 1930’s when they observed a
substance in the serum of individuals with Pneumococcus infections. It formed a
precipitate when mixed with the C-polysaccharide coat of Streptococcus pneumonaie.
Upon further examination it was noted that this “C-reactive” activity was absent from
the sera of healthy individuals. It was MacLeod and Avery who subsequently
characterised this substance as a protein and Lofstrom who established that CRP is a
non-specific acute-phase protein (Ledue 2001).
CRP, composed of 5 identical non-glycosylated polypeptide subunits belongs to a
family of proteins known as pentraxins. Each of the 5 subunits consists of 206 amino
acid residues with a calculated molecular mass of 23kD and thus a total molecular mass
of 118kDa. The structure of CRP (see figure 1.1) contains a crystal contact where the
calcium binding loop from one protomer co-ordinates into the calcium site of a second
protomer to form the pentameric structure (Ledue 2001).

Fig. 1.1 Structure of CRP; Copyright Olympus

CRP has a half-life of approximately 19 hours. It is regulated by interleukin 6 (IL6),
Interleukin 1 (ILl), tumour necrosis factor alpha (TNF-alpha) and other cytokines.
The precise in vivo role of CRP is unclear however its properties are consistent with a
fundamental role as a non-specific defence mechanism. It opsonises bacteria, promotes
agglutination, and increases phagocytes at the site of inflammation (Pepys 2003). CRP
synthesis occurs in response to tissue injury or infection and concentrations may
increase 10,000 fold. The plasma half-life of CRP is constant under all conditions of
health and disease and the sole determinant of CRP concentration in a system is the
synthesis rate. Its concentration therefore reflects the intensity of the pathological
processes stimulating CRP production (Ledue 2001). CRP baseline concentrations are
influenced by various chronic microbial infections (Black 2004), a proatherogenic
metabolic state (Libby 2004), smoking (Yen 2006), coffee consumption (Zampelas
2004), stress (Melamed 2004), oral contraceptives (Dreon 2003) and menstrual cycle
(Jilma 1997). Recent studies have also shown that genetic variations in the CRP gene
influence circulating CRP concentrations (D'Aiuto 2005) and the genetic factors
regulating CRP concentrations also modulate the individual response to endotoxin
stimulated inflammation (Marsik 2006).

1.1

Clinical Applications of CRP

The American Heart Association, in 1998, convened Prevention Conference V to
examine strategies for the identification of high-risk patients who need primary
prevention. As part of this conference the measurement of markers of inflammation
was given consideration. The conference concluded that “many of these markers
(including inflammatory markers) are not yet considered applicable for routine risk
assessment because of (1) lack of measurement standardization, (2) lack of consistency
in epidemiological findings from prospective studies with end-points, and (3) lack of
evidence that the novel marker adds to risk prediction over and above that already
achievable through the use of established risk factors.” Since this publication however
several commercial assays for inflammatory markers have become available and a
large number of scientific reports have been published relating inflammatory markers
to cardiovascular disease (Pearson 2003).
Research indicates C-reactive protein can contribute directly to arteriosclerosis (Nissen
2005). Inflammatory states generate cytokines that, as mentioned previously, induce
the synthesis and release of CRP. Elevated levels of CRP can injure arterial
endothelium, thereby promoting the generation and progression of arteriosclerosis.
Atheriosclerotic lesions can in turn be the source of additional synthesis and release of
cytokines and CRP (Labarrere 2004). Decade to decade consistency of values for CRP
is similar to that of values for blood pressure and total cholesterol concentration,
suggesting that this inflammatory marker is sufficiently stable for potential use in the
long-term prediction of CRP (Danesh 2004).

1.1.1

CRP and Angina

Early studies carried out on the prognostic value of CRP in severe unstable angina
found that 65% of patients admitted to hospital with unstable angina had elevated
levels of CRP. Of patients admitted with acute myocardial infarction, 76% had an
elevated CRP level. All patients with unstable angina who had levels of acute phase
reactants >/=0.3mg/dl (65%) had more ischemic episodes in the hospital than those
with levels below this concentration. An ischemic episode is one that is caused by a
lack of blood going to a particular organ and is usually due to a blocked artery. In this
case the ischemic episodes refer to the symptoms of lack of blood travelling to the
heart.
Of those with elevated CRP and unstable angina, 25% suffered myocardial infarction
and 10% died. In contrast no deaths or myocardial infarction occurred among the
patients with levels of acute-phase reactants < 0.3 mg/dl. The study concluded that an
elevated level of CRP (and serum amyloid A protein) at the time of admission to
hospital predicts a poor outcome in patients with unstable angina (Liuzzo 1994).

1.1.2

CRP and Cardiac Risk

Facilitated by the eommereial availability of automated CRP assays there has been a
vast number of studies of CRP in cardiovascular disease and associated conditions
(Ridker 1997). In a population-based study derived from general praetice registers in
Great Britain, each doubling of highly sensitive -CRP (hs-CRP) concentration resulted
in a 1.5 fold inerease in the occurrence of CAD (Coronary Artery Disease) among 388
men aged 50-69 years (95% eonfidence interval) (Mendall 1996).

Regarding patients with established vaseular disease, the European Concerted Action
on Thrombosis & Disabilities Study (ECAT) found that among 2121 patients with
angina, each standard deviation increase in base-line hs-CRP was associated with a
45% inerease in the relative risk of non-fatal myocardial infarction (MI) or sudden
cardiac death (95% Cl for relative risk 1.15-1.83) over two years of follow up (Morrow
2000). Current risk factors associated with cardiovascular disease are obesity, smoking,
hypertension, diabetes mellitus, and hyperlipidemia. Many of the therapies for these
disorders also reduce CRP levels. Measuring hs-CRP levels could be useful to motivate
patients with moderate-to-high cardiovascular risk to improve their lifestyles or to
comply with drug therapies. A review of therapies that target C-Reactive Protein for
primary prevention and for the treatment of atheriosclerotic diseases concluded it is
certainly reasonable to consider measuring hs-CRP levels in patients with
eardiovascular disease in the absence of known risk factors. Once risk is established,
however, there is little evidence upon which to base repeated assessment of C-reactive
protein levels (Labarrere 2004).

The Reykjavik study was initiated in 1967 as a prospective study of cardiovascular
disease. A study nested within the Reykjavik Study found that the odds ratio for
coronary heart disease was 1.92 (95% Cl, 1.68-2.18) in a comparison of participants in
the top third of the group with respect to base-line CRP values with those in the bottom
third. The odds ratio fell, however, to 1.45 (95% Cl 1.25-1.68) after adjustment for
smoking status, socio-economic status and other established risk factors. Measurements
were made in samples obtained at base line from 2459 patients who had a non-fatal
myoeardial infarction or died of coronary disease during the study and 3969 controls
without a coronary heart disease event. This study concluded that in comparison with
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major established risk factors, such as an increased Total Cholesterol concentration and
cigarette smoking, the CRP concentration was a relatively moderate predictor of the
risk of CHD and added only marginally to the predictive value of established risk
factors for CHD (Danesh 2004).
Area under the ROC
Curve (95% Cl)

Risk Factor
Tolat chote&lerol

0.61 (0.59-0 62)

Current cigarette srnoking
(us. nonsmoking)

0,63 (0.61 0.64)

Systolic blood pressure

0.64 (0.63-0.65)

C-reactn/e protein

0,65 (0.64-0 67)

Erythrocyte sedimentation
rate

0.65 (0.64-0,67)

von Willebrand factor

0.66 (0.64-0.67)
1

2

4

Odds Ratio for Coronary Heart Disease

Fig. 1.2 Odds Ratio for Coronary Heart Disease among 2459 Patients with CHD and 3969 Controls. “CReactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart
Disease." N Engl J Med 350(14): 1387-1397

1.1.3

CRP and Prediction of Cardiovascular Disease in Women

In data derived from the Women’s Health Study (WHS) it was found that of 12
markers measured (including Serum Amyloid A, homocysteine and soluble
intercellular adhesion molecule type 1) hs-CRP was the strongest univariate predictor
of the risk of cardiovascular events. Each marker of inflammation improved riskprediction models based on lipid testing alone, an effect that was strongest for hs-CRP
and serum amyloid A. Cardiovascular events were defined as death from coronary
heart disease, non-fatal myocardial infarction or stroke, or a coronary revascularization
procedure. With use of these criteria 122 case subjects and 244 age and smoking
matched control subjects were selected from the 28,263 strong Women’s Health Study.
Those with levels of hs-CRP in the highest quartile were at nearly five times the risk of
any vascular event (Relative Risk (RR) 4.4, 95% confidence interval, 2.2 to 8.9). Even
after adjustment for BMI, hypertension, diabetes, or a parental history of premature
myocardial infarction, and the level of HDL cholesterol, the increased risk for women
in the highest quartile of hs-CRP at base-line remained statistically significant (R.R.
3.1, 95% confidence interval, 1.1 -8.3) (Ridker 2000) - see Table 1.1 below.
I'hese risk estimates are consistent with findings in men and persisted among multiple
low-risk sub-groups examined. Models that included hs-CRP in addition to the lipid
profile had a prognostic advantage over those that did not. Moreover the predictive
value of hs-CRP in the WHS was significantly larger than homocysteine - another
emerging risk factor (Morrow 2000).

Variable
Hs-CRP
Median - mg/dl
Relative Risk (95% Cl)
LDL Cholesterol
Median - mg/dl
Relative Risk (95% Cl)
HDL Cholesterol
Median - mg/dl
Relative Risk (95% Cl)

Quartile of Plasma Level

P Value
Trend

0.06
1.0

0.19
2.1

0.38
2.1

0.85
4.4

<0.001

88.4
1.0

108.9
0.9

127.4
1.7

156.6
2.4

0.001

34.5
1.0

44.5
0.5

54.9
0.5

68.5
0.3

0.001

for

Table 1.1 Data adapted from "C-Reactive Protein and Other Markers of Inflammation in the Prediction
of Cardiovascular Disease in Women." N Engl J Med 342(12): 836-843.
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1.1.4

CRP and Hormone Therapy

Oestrogen is considered to have many beneficial cardiovascular effects in women
(Ogita 2003). Cessation of ovarian function and sex hormone deficiency are therefore
associated with metabolic disorders that increase the risk of cardiovascular disease in
women after menopause (Davidson S. 2003). An investigation into the relationship
between hormonal status and cardiovascular risk, assessed by inflammatory markers
including CRP, in menopausal women yielded the following results.

The study concluded inflammation states in clinically healthy women were not affected
by the concentration changes of sex hormones at the menopausal transition. Of the
inflammatory markers measured only the sICAM-1 concentration in menopausal
women significantly exceeded that in pre-menopausal women. It was concluded that
the impact of menopause on increased cardiovascular risk seems to be related mainly to
BMI, insulin resistance and increased triglyceride and sICAM-1 concentrations. It was
shown using the algorithms proposed by Rifai and Ridker (Rifai 2001) that the highest
calculated cardiovascular risk was two times more likely among healthy post
menopausal

women

than

pre-menopausal

and

associated

more

so

with

hypercholesterolemia than with CRP concentrations. Changes in the concentrations of
the sex hormones at the menopausal transition did not directly influence the
inflammation state in clinically healthy women (Stefanska 2005).

So what are the effects of hormonal treatments on circulating CRP concentrations in
men?

It was seen among one group of middle-aged men that when half were treated for
prostate cancer by orchidectomy (an operation to remove the testicles as a means of
controlling the prostate cancer) and half with oestrogen that those who were treated
with oestrogen had twofold higher CRP concentrations than those patients who
underwent orchidectomy (Kovacs 2005). This pronounced effect on circulating CRP
concentrations in men, although contradicting Stefanksa above, gives further support to
results of previous studies of oral contraceptives and hormone replacement therapy in
women (Davidson S. 2003).
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1.1.5

CRP and CHD Prediction in Children

The efficacy of measuring CRP concentration in children and young adults to assess for
cardiovascular disease risk remains open to speculation. Carotid intima-media
thickness in children and endothelial dysfunction was recently associated with CRP
concentration (Jarvisalo 2002). A study of 699 British children showed previously that
CRP concentration was associated with systolic blood pressure, diastolic blood
pressure, pulse, fibrinogen concentration, factor Vile, HDL-cholesterol concentration,
triglyceride concentration, apolipoprotein B concentration and post load insulin
concentration after adjustment for age, sex, ethnicity, and town. Further adjustment for
ponderal index (similar to body mass index) attenuated most of the Pearson correlation
coefficients to some degree and caused some of the previously significant associations
to lose their statistical significance. Other studies have also demonstrated that excess
weight is strongly associated with CRP concentration in children. Thus, children with
abnormal values for cardiovascular risk factors are likely to have increased CRP
concentrations. Data from 3348 US children and young adults 3-19 years of age who
participated in the National Health and Nutrition Examination Survey, 1999-2000, was
used to describe the distribution of CRP concentrations. This data assessment study
found that the median CRP concentrations in children and young adults are far below
the levels associated with cardiovascular risk among adults. It was concluded that
although CRP levels may be valuable for identifying adults at high risk for
cardiovascular disease, particularly among those with lipid concentrations within
reference intervals, further investigation is required before extending this proposition to
children and young adults (Ford 2003).
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.6

Medical Decision Levels of CRP

Cardio CRP Value (mg/L)
<1

Coronary Heart Disease Risk Level
Low

1-3

Medium

>3 (up to 10)

High

Inflammatory CRP Value (mg/L)

Inflammation Level

10- 1000

High

Table 1.2 Data Obtained from American Heart Association

1.1.7

CRP and Neonatal Samples

Infection within the first 48 hours of birth is a serious condition and any delay in
treatment can result in death. Because the presenting symptoms are often subtle and
non-specific such infections are normally difficult to diagnose and the decision to start
anti-microbial therapy was therefore frequently based on clinical grounds alone
(Wasunna 1990). Traditionally neonatal analysis following bacterial infection has
depended mainly on blood and cerebral spinal fluid (CSF) cultures. Speed in treating
the patient however is crucial with neonates so availability of a sensitive test capable of
giving rapid results is of considerable value in the management of this clinical problem.

Umbilical cord blood normally has very low levels of CRP - usually approximately
0.12mg/l. Given this accepted median concentration measurements of CRP which yield
two high results 24 hours apart strongly indicate the presence of infection. Similarly
two low values of CRP measured 24hrs apart would suggest absence of any bacterial
infection (Benitz 1998). Furthermore, certain viral infections can also increase plasma
CRP concentrations, as occurs in invasive bacterial infections (Matesanz 2003).
Consequently CRP concentrations provide a reliable guide to institute antibiotic
treatment (Hatherill 1999).
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Upon initiating treatment of an infection, CRP assays provide an invaluable tool in
assessing the effectiveness of this treatment. Alternative remedies may be tried based
on continued elevated levels of C-reactive protein.

1.1.8

CRP and Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (DM), estimated to affect 15 million Americans, is growing
in incidence and is associated with an increased risk for cardiovascular disease.
Although the main symptoms and physiological abnormalities of Type 2 DM are well
documented, the specific causes of these metabolic defects remain uncertain. Research
shows that inflammation plays a role in pathogenesis, thus linking diabetes with a
number of commonly coexisting conditions thought to originate through inflammatory
mechanisms. Another study suggests that Type 2 DM may represent a disease of the
innate immune system (Pickup 1998). A prospective, nested case-control study
involving participants in the Women’s Health Study investigated the role of two wellknown biomarkers of inflammation, interleukin 6 (lL-6) and C-reactive protein, in
Type 2DM. Case subjects were participants who provided blood samples, were free of
reported diabetes at enrolment and subsequently developed newly diagnosed diabetes
during a 4-year observation period. Subjects who were diagnosed within the first year
of follow-up were excluded due to the high prevalence of undiagnosed diabetes.
Control subjects were matched by age and by the fasting status of their blood samples.
CRP was measured by a hs-latex enhanced immunonephelometric assay on a BN 11
analyser and lL-6 was measured using a commercially available ELISA. Results
showed significantly higher median baseline levels of IL-6 and CRP among case
studies versus controls. In age-matched analyses the relative risks for Type 2 DM for
increasing quartiles of CRP were 1.0, 2.2, 8.7 and 15.7 respectively (P<0.001 for
trend). Results for lL-6 showed a similar trend. Adjustment for BMl attenuated these
results, however CRP remained a significant predictor of Type 2 DM. Overall, the
relative risk(RR) for future diabetes increased 28% per quartile increase in IL-6 and
64% per quartile increase in CRP. This data raises the possibility that CRP may be not
only useful as an inflammatory and cardiac marker but also as a tool in the early
detection of risk or Type 2 DM (Pradhan 2001).
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1.1.9

CRP and Polycystic Ovarian Syndrome

Individuals with polycystic ovarian syndrome (PCOS) are seen to have an inverse
relationship between their CRP concentration and sensitivity to insulin (Kelly 2001). In
order to fully assess the relationship between these two measures the biological
variability of CRP and insulin resistance within the same individuals with PCOS must
be calculated. One study attempted to establish if a PCOS patients CRP concentration
remains within narrow biological limits or varies more widely over a given time period
and to correlate its variability to that of insulin resistance. The study was carried out on
12 Caucasian women diagnosed with PCOS and 11 weight matched Caucasian women
without PCOS as controls. It was found that although the mean concentration of CRP is
higher in individuals with PCOS than in those without, the intra-individual variation of
CRP is similarly large in both groups. This intra-individual variation was of a
magnitude that prompted Cho et. Al. to suggest that perhaps the utility of CRP as a
marker of CHD could be limited - in this instance a substantial overlap was seen
between PCOS and the healthy controls patients.

The lack of concordance between the variability of CRP concentration and the
variability of insulin resistance in patients suffering from PCOS indicated that despite
the known inverse relationship, the extent of CRP changes in the same individual does
not closely mirror that of insulin resistance. Consequently it would not be feasible to
use CRP concentration as a marker to establish the presence of insulin resistance in this
group. The study concludes that the CRP concentration possibly reflects one of the
many factors that contribute to polycystic ovarian syndrome (Cho 2005).
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1.1.10 CRP and Percutaneous Coronary Intervention

Percutaneous Coronary Intervention (PCI) encompasses a variety of procedures used to
treat patients with diseased arteries of the heart. Several studies have shown that
increased concentrations of baseline circulating CRP in patients undergoing PCI is
associated with the outcome, either short or long term (Buffon 1999). A more recent
study however has aimed to evaluate whether the CRP response to PCI might also have
a prognostic value. Eight hundred and ninety one consecutive patients presenting with
stable or unstable angina pectoris, with serum concentrations of cardiac tropinin T </=
0.03 ug/L, who were undergoing a variety of PCIs were investigated. The follow-up
time varied between 6mths and 4.6 years. Results showed that patients with death or
nonfatal MI at the endpoint of the study had increased baseline CRP concentrations
(3.08 (1.21-7.07) vs. 1.76 (0.85-4.12) mg/L) and CRP response to PCI of 2.69(0.539.66) mg/L vs. 1.4 (0.37-3.29) mg/L compared to those without such endpoint
outcomes. It was thus concluded that CRP measurement the day after PCI when
considered with baseline CRP measurement contained considerable prognostic value
and associated with an increased risk for death or nonfatal MI in multivariate analyses
(Saleh 2005).

A previous study did however find that treatment with clopidogrel

before PCI attenuates the CRP response to the procedure (Vivekananthan 2004)therefore one of the limitations of Saleh’s study was that results could therefore not be
extrapolated to patients treated with clopidogrel.

Fig. 1.3 Box plots of CRP concentrations before (U) and in response to PCI (^) according to death or
nonfatal myocardial infarction. Adapted from Response of Serum C-Reactive Protein to Percutaneous
Coronary Intervention Has Prognostic Value. Clin Chem (Saleh 2005).

1.2

Latex Assays

Latex particles have been widely used in recent years in the development of a broad
range of immunoassays. These range from the original “latex” agglutination tests first
introduced by Singer and Plotz in 1956 (Singer 1956) to more recent assays such as
particle capture Elisa’s, turbidimetric immunoassays, dyed particle sandwich tests, and
solid phase assays using silica or magnetic micro spheres. Many common immunology
methods are based on microparticle enhanced assays, the use of colloidal particles to
enhance the antigen-antibody reaction being one of the most important. The basic
principle underlying this assay method is that antibody-coated microparticles are crosslinked and aggregated by the complementary antigen present in a biological sample.
The colloidal agglutination in the system can then be measured by various optical
techniques. An advantage of this type of immunoassay is that it offers a simplistic test
with a high sensitivity (Ortega-Vinuesa 1997). In these assays the particles serve two
purposes: (a) to enhance the light scattering achieved on reaction of antigen with
antibody and (b) to act as a core particle in the development of an immunoinhibition
assay (Thompson 1997). By using a common antibody with IgG as a model analyte, the
development of a non-enhanced and a latex-particle-enhanced turbidimetric assay for
measuring serum IgG it was observed by Thakkar et. Al. The results for both assays
compare well with those by rate nephelometry. The latex-enhanced assay had
equivalent sensitivity, working range, and interassay precision, but much greater signal
change and calibration stability than the non-enhanced assay. It was also noted that
with latex particles less antiserum was needed. Coupling antibodies to latex particles
offers considerable advantages even when an improved assay detection limit is not
required (Thakker 1991).

Polystyrene-based microparticles are negative charge-stabilised eolloidal particles.
Polystyrene is made by an addition reaction using styrene monomer, initiator, buffer
and surfactant. Chain initiation occurs when a sulphate free radical reacts with the
double bond of a styrene monomer. The resulting styrene free radical reacts with the
additional molecules of styrene to produee high molecular weight chains of
polystyrene. Chain termination occurs when two growing chains react to make a
sulphate terminated polymer chain.

19

A minimum amount of negative surface charge is required to maintain colloidal
stability of these polystyrene microparticles. Negative charge supplies a repulsive
electrostatic charge to counteract the inherent attractive van der Waals force. There
have been various studies carried out on the effects of protein adsorption, pH, ionic
strength and detergents on the stability and surface charge of latex particles and results
would indicate that all of these factors affect the stability of the latex solution. These
contributors should be carefully considered when developing a workable diagnostic
assay (Thompson 1997). The particles used throughout this project were prepared by
emulsion polymerisation with an anionic detergent, with the stabilising negative charge
on these particles being supplied by a combination of surface sulphate groups and
adsorbed anionic detergent.

1.2.1

Protein Adsorption to Microparticles

Proteins may be bound to polystyrene microparticles (PS-MPs) by adsorption,
mediated by hydrophobic and ionic interactions between the protein and the surface of
the microparticles. An early study carried out by Singer and van Oss, looking at the
adsorption of radiolabelled proteins to PS-MPs, concluded that IgG binds solely by
hydrophobic or van der Waals forces (van Oss 1966). Another study of the effects of
pH on binding of IgG to polyvinyl toluene MPs found maximum binding occurs at the
isoelectric point of IgG, which is at a pH of 7.8. The binding of IgG was seen to
decrease linearly as pH was changed in either direction from the isoelectric point
(Bagchi 1981).

The non-covalent forces, which bind IgG to a PS-MP, are individually weak however
extensive contact between protein and particle surface strengthens these bonds making
the adsorption mainly permanent. Complete desorption is described as being
“energetically less favourable than adsorption, because adsorption can be achieved by
single contact but desorption must be accompanied with breaking of all contact points”
(Bag chi 1981). The primary factors affecting the adsorption of proteins to polystyrene
MPs, as illustrated by Seradyn Inc., are pH, ionic strength, protein properties and
charge density of the microparticle (Griffin 1994).
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Before addition of protein to the microparticles, the microspheres’ surface capacity for
the protein being used should be known. The surface area of a uniform microparticle
suspension may be calculated with the formula S=5.71/D, where S is the surface area in
meters squared per gram of MP and D is a particles diameter in microns. If simple
adsorption of Ab or Ag onto the microparticle is insufficient for requirements, it is also
possible to adsorb the protein by more complex methods for example co-adsorption
with BSA or cross-linking with adsorption.

Proteins can also adsorb rapidly to carboxylate-modified microparticles. It is reported
that binding of IgG and BSA to acrylic acid modified PS-MPs was greater than to plain
PS-MPs. Not considered to be caused by increased surface hydrophilicity, this
increased binding has been attributed to hydrogen bond formation between protein
molecule and MP carboxyl groups (Griffin 1994).

1.2.2

Covalent Coupling of Protein to Microparticles

In order for microparticles to undergo covalent coupling to a protein they must have a
functional group capable of forming a bond with suitable side chains of the protein.
Polystyrene Microparticles (PS-MPs) may be modified by copolymerising styrene with
a small amount of functional hydrophilic monomers. These adapted MPs offer altered
binding properties and generally increased colloidal stability. Many of the co
monomers also provide chemically reactive groups for covalent coupling of protein.
Microparticles copolymerised with acrylic acid for example give readily available
surface carboxyls useful for covalent coupling to protein amino groups. Other acids and
monomers can be used to yield particles with different surface chemistries.
Proteins can be covalently coupled by either a one or two-step process. The benefits of
covalent coupling of antibodies to latex particles have been demonstrated for many
analytes such as urine albumin (Medcalf 1990), serum p2-microglobulin and CReactive Protein (Price 1987).
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.2.3

One Step Process Covalent Coupling

Carboxylate-modified microparticles (CM-MPs) can covalently attach proteins via
water-soluble

carbodiimide

chemistry,

through

the

use

of

1-ethyl-3-

(-

dimethylaminopropyl)-carbodiimide (EDC or EDAC). EDAC is a zero-length crosslinking agent used to couple carboxyl groups to primary amines. The carboxyl groups
on the MPs, activated by the EDAC, react with free amino groups of the adsorbed
protein to form amide bonds. This cross-linker has been used in diverse applications
such as forming amide bonds in peptide synthesis, attaching haptens to carrier proteins
to form immunogens, subunit studies and protein-protein conjugation (Pierce).
watersoluble

carbodiimide
Immunochemical
(with amino group)

/

-

Microsphere with immunochemical
bound via amide bonds

Fig 1.4 One step Covalent Coupling. Tech Note # 201 Working with Microspheres, Bangs Laboratories
Inc

1.2.4

Two-Step Process Covalent Coupling

Although one-step coupling is largely effective, there are some distinct advantages to
choosing a two-step process for covalent coupling. EDAC is an indiscriminate cross
linker and to avoid uncontrolled clumping of the microparticles the two-step process is
often favoured. As with one-step coupling the -COOH groups on the microparticle are
activated with EDAC. Once active the carboxyls are then further reacted with an active
alcohol, e.g. NHS, to form an active ester. This amine reactive ester then forms amide
cross links with the protein. Another advantage to two-step process versus one-step is
the longer half-life of the active ester over the EDAC species. (Staros 1986).
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.2.5

1.

Covalent Vs Passive Coupling

When the required concentration of antibody is high it may be possible to
achieve greater levels of protein on the surface using covalent coupling than
by passive binding alone (Bangs-Laboratories Technote 201). Also if the
desired coverage is low, it may be easier to control coating level and
uniformity by covalent coupling.

2.

Extremely sensitive assays can be influenced by the slightest change on
protein concentration on the surface of the microparticle. If the protein was
to become even faintly de-adsorbed from the microparticle this could have
grave consequences for the performance of the assay.

3.

Increased lot-to-lot reproducibility and a more thermally stable reagent are a
result of covalent coupling.

4.

After covalent attachment, the protein will not come off the surface. It is
possible to add as much surfactant as necessary (maybe even 1% Tween) to
eliminate non-specific binding. Adding this much surfactant to adsorbed
protein/microspheres could displace unbound protein, but not adding the
surfactant could result in significant interference from serum effects in
samples.
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1.3

Current CRP Assays

Initially the main application for CRP was as an inflammatory marker; consequently
commercial assays had measuring ranges from approximately 10-300mg/L. As CRP
emerged as a potential cardiac marker however, market requirements for a more
sensitive assay became greater and more emphasis was placed on detection of low
levels of CRP. Because of its consequences in clinical practice and in epidemiological
research, the issue of the precision of each method and the agreement among different
methods cannot be over emphasised for CRP, as well as for other markers of disease.
Poor precision of a given method resulting from inaccurate measurement readings may
lead to overestimation of the true occurrence of patients with abnormal values and a
serious underestimation of the association between CRP levels and the occurrence of
adverse events in epidemiological research. Furthermore, poor agreement stemming
from systematic differences among different methods can have implications in the
choice of the cut-off points above which cardiovascular risk increases so that
therapeutic interventions are recommended (Maggiore 2005). While prospective
studies have shown that CRP can potentially be used as a predictor in the risk of future
cardiovascular events,

hs-CRP assays can only be considered suitable

for

atheriosclerotic risk stratification if standardisation is improved (Hamwi 2001).

The Centres for Disease Control and Prevention (CDC, Atlanta, GA) initiated a
standardization program in which manufacturers of all hs-CRP assays worldwide were
invited to participate (Kimberly 2001). The aim of the CDC is to develop primary and
secondary reference materials and a primary reference method. Phase I of the CDC
project aims to identify the suitable reference materials (Kimberly 2003) to use in the
harmonization of the various hs-CRP assays (Phase II). The analytical performance and
clinical utility of several assays have been studied and are discussed below. (Lolekha
2005).
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1.3.1

Particle Enhanced Automated Assay Versus Elisa

The clinical efficacy of one such automated and commercially available assay has been
compared to a validated in-house Elisa, previously shown to prediet future Peripheral
Arterial Disease (PAD) in asymptomatic populations. The reference method was an inhouse eompetitive Elisa, which used polyclonal anti-CRP antibodies and a calibrator
that was traceable to WHO Reference Material 85-506. The second method, which
used particle enhanced technology by Dade Behring, was performed on the Behring
BN II nephelometer and used monoclonal anti-CRP antibodies. Its calibrator was also
traceable to the WHO Reference Material. The study population eonsisted of 144
apparently healthy men aged between 40-84 years of age, participating in the
Physician’s Health Study (Steering Committee of the Physician’s Health Study
Research Group) who subsequently developed symptomatic PAD and 144 age and
smoking matched controls who remained free from disease during the 60 month follow
up period. A very high correlation was found between the two hs-CRP assays and all
but two participants were classified into the same quartiles or varied by only one
quartile. As expected the median CRP concentration of the ease group was signifieantly
higher than that of the control group when measured by both the automated assay and
by the Elisa method. Moreover, the calculated relative risks of developing PAD
increased significantly with each increasing quartile of hs-CRP for both Latex and
Elisa methods. The calculated interquartile increase in relative risk of PAD was 31%
for the Elisa method and 34% for the Latex method. The study concluded that the latex
method is equally as efficacious as the validated Elisa method in classifying patients
into cut-off points established by prospective studies for risk stratification for coronary
and cerebrovascular disease (Rifai 1999).

1.3.2

Studies using Dade Behring as Reference Method

This Dade Behring assay in turn became a reference method for further investigations
of eommercial hs-CRP assays. In one study this assay was compared to the Abbott
IMx, the Diagnostics Products Corporation IMMULITE and the Beckman Coulter
IMMAGE. This study evaluated the four assays and the implications of the results for
clinical and epidemiological applications. All assays were evaluated for precision and
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linearity with samples from 322 apparently healthy blood donors. The imprecision of
the BN II, IMx, IMMULITE and IMMAGE methods were <1=1.6%, </=I2%, </=9.8%
and <1=9.1% at 3.5mg/L respectively and linear down to </=0.30, </=0.32, </=0.85 and
</= 2.26mg/L respectively. The four methods exhibited different results within the
healthy population samples and the study concluded that additional standardization
efforts were required to ensure hs-CRP results could be related to large-scale
epidemiologic studies (Roberts 2000). Part 2 of the study evaluated nine automated
high-sensitivity C-reactive protein methods and the associated implications for clinical
and epidemiological applications. Methods compared were the Dade Behring, Daiichi,
Denka Seiken, Diagnostic Products Corporation, latron, Kamiya, Olympus, Roche and
Wako. With samples from 388 apparently healthy individuals these assays were
evaluated for limit of detection, linearity, precision, prozone effect and comparability.
Again, based on previous analytical and clinical validations, the Dade Behring BN II N
High Sensitivity CRP assay was used as the comparison method. All assays examined
had limits of detection < 0.32mg/L and were linear over the concentration range 0.2lOmg/L. According to the manufacturers, all of the methods were standardised against
the IFCC Certified Reference Material (CRM) 470 standard rather than the older WHO
material 85/506. The methods evaluated in this group could be separated into two
groups based in their ability to classify subjects into quartiles of hs-CRP. The first
group, including Denka Seiken, DPC, latron and Wako, classified 92-95% of subjects
into the same quartile as the reference method. The second group, including Daiichi,
Kamiya, Olympus and Roche, classified 68-77% of subjects into the same quartile as
the Dade Behring reference method. Additionally, considerable positive bias relative to
the comparison method was noted. hs-CRP concentrations corresponding to the 75**^
percentile for the latter group were equivalent to the 80^*^ percentile concentrations for
the former group. Significantly, none of the examined assays misclassified by more
than one quartile. The study concluded that although more standardisation is needed to
harmonise results from the various methods, the overall performance of the assays is
promising (Roberts 2001).

Another comparison between the Tina Quant CRP immunoturbidimetric method
(Roche)

and

the

Dade

Behring

N

high-sensitivity

latex-enhanced

immunonephelometric method in 4228 Asian sera samples showed that almost all
patients were classified into the same tertile by both methods. Only 0.2% of the
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subjects disagreed by more than one tertile. Both methods were considered to be
suitable for screening larger populations.
This study highlights another important aspect of CRP screening - perhaps the cut offs
for CRP, which are currently derived from a Caucasian population (Pearson 2003), are
not entirely appropriate for Asian populations. Although previous studies have
indicated that there is no need for ethnic specific cut offs in the Japanese (Yamada
2001), American (Rifai 2003) and European demographics (Imhof 2003), Lolekha et.
al. suggest that this is not the case where the Asian population is concerned.

1.3.3

CRP Assays for Patients with Uremia

Similar studies have not yet been carried out in subjects with uremia. In an effort to fill
this gap one study evaluated precision and agreement of 3 commonly used automated
methods for measurement of CRP levels in these individuals. Chronic inflammation
has been repeatedly reported in individuals undergoing haemodialysis. As an
inflammation marker, therefore, CRP measurements could be considered useful in
patients undergoing such treatment.

The immunoturbidimetric Olympus assay was

compared to the nephelometric Dade Behring and Beckman assays. On average the
Behring method yielded higher CRP values than did the other two methods while on
average the Beckman and Olympus methods yielded similar results over the entire
range. Significantly however are the potential clinical implications of CRP levels at
decision level cut-off points. Once taken into account, substantial disagreement was
seen between the Beckman method and the other two methods. In some instances the
Beckman method provided CRP values of 0.06mg/L whereas the other methods
yielded values 10-100 times higher. This disagreement involved the range of CRP
values most clinically useful in determining which patients are at greater risk of
cardiovascular disease and malnutrition. No reason for these discrepancies is known.
The authors of the study concluded that a move towards standardisation is imperative
as false positive or negative CRP values in patients may lead to inappropriate
diagnostic and therapeutic decisions (Maggiore 2005).
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1.3.4

CRP Point of Care Tests

The accepted criteria for Point of Care Tests include affordable cost, a disposable
device and minimum maintenance/technical expertise required to perform tests (Brooks
1999). Although automated immunoassays are an invaluable tool in diagnosis they can
often be expensive or slow when an immediate result is required.

The technical performance and robustness of NycoCard® CRP Whole Blood, a near
patient test for CRP, was assessed when used in realistic daily routine situations in
general practice clinics (GPCs). Results from the GPC’s were compared with results
from a turbidimetric lab method, which was traceable to IFCC CRM 470. The
advantage of a CRP test while the patient is still in the surgery is immense - avoidance
of unnecessary prescription by allowing the doctor to distinguish between viral and
bacterial infection. Overall results obtained by this test were consistent with the results
obtained at the lab and no major systematic bias was observed between the two
methods. The study concluded that the NycoCard® CRP test for whole blood with
visual evaluation of results is as good when used in GPCs as could be expected from
laboratory testing in terms of bias and precision as a semi-quantitative test for near
patient testing (Steen 1997).

More recently a fluorescence hs-CRP immunoassay for point-of-care testing was
assessed and good correlation was found between this assay and the BN 11
nephelometry assay method (Oh 2005). This assay, commercially known as iCHROMA™, was seen to provide fast, reliable and fully reproducible results in
comparison with fully automated methods, with a working range from 0.15-50mg/l The
technical performance of the assay was assessed in terms of linearity and imprecision
to evaluate if the /-CHROMA™ system could be a reliable point of care test platform
in comparison with other automated assay methods. Oh et. al. concluded that while
automated immunoassays have an advantage for quantification of hs-CRP in large
numbers of samples, the /-CHROMA™ is well suited for point of care testing of whole
blood.
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1.4

Assay Requirements

The FDA introduced guidance for industry and FDA staff in September 2005 to
provide recommendations for manufacturers of CRP assays and to address issues
associated with the development of hs CRP and cardiac CRP assays. This document
now includes discussion of how claims for appropriate used of CRP assays should be
supported. Although not legally enforceable, these guidelines do reflect the FDAs
current thinking on this topic. “A manufacturer who intends to market a CRP test
system should conform to the general controls of the Federal Food, Drug and Cosmetic
Act (the Act), including the premarket notification requirements described in 21 CFR
807 Subpart E, and obtain a substantial equivalence determination from FDA prior to
marketing the device.” CRP assays are FDA Class II devices, which means general
controls alone are not sufficient to assure safety and effectiveness. In addition to
complying with general controls. Class II devices are also subject to special controls.
The CRP assay is divided into three classifications - conventional CRP, the standard
broad range assay for detection of inflammation. High Sensitivity CRP and Cardiac
CRP, both of which are sensitive assays with cut-off values below l.Omg/L. It is
recommended that, for the sensitive assays, a comparison be carried out between the
assay being introduced and a predicate assay and they should be at a minimum
traceable to IFCC/BCR/CAP CRM 470.
The FDA recommend the assay be evaluated for use with respect to precision (within
run and total), interference, sensitivity, linearity and stability. Where possible, it is
recommended that the performance be assessed in the testing environment where the
assay will ultimately be used. All claims regarding performance of the assay should be
substantiated as failure of a CRP assay to perform as indicated may lead to improper
patient management (Guidance for Industry and FDA Staff Doc # 1246).
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1.5

Olympus Analysers

The Olympus System Analysers carry out automated analysis of serum, plasma, urine
and CSF. The three main Olympus analysers are the AU400, AU640 & AU2700 and
these share many common features as can be seen from the specifications in Fig. 1.7.
The AU400 is the smallest of the instruments and is best suited to smaller laboratories
with a low throughput. The most popular of the instruments is the AU640, tailored to
meet the needs of a busier medium sized laboratory. Laboratories with a high
throughput would benefit from the use of an AU2700, which has a measuring capacity
of 1600 tests per hour.

Fig. 1.5 Schematic Diagram of Olympus AU2700
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Samples to be tested are placed in racks on a feeder belt and entered into the system.
The reagents are stored in refrigerated compartments between 4 & \2°C to prevent
deterioration. Reagent 1 is dispensed by a robotic syringe into a cuvette and mixed into
a homogenous solution with a small volume of the sample to be tested. Reagent 2, if
required, is then added to the cuvette and the solution is mixed once more. The solution
then passes the photometer, where light is passed through the solution, and the analyser
measures the resulting change in optical density. The reaction temperature is 37°C and
all of the analyser cuvettes are maintained at this temperature. Concentration of the
analyte being measured is proportional to the optical change. The samples can be
measured at thirteen different wavelengths (340, 380, 410, 450, 480, 520, 540, 570,
600, 660, 700, 750 and 800nm) within a reaction time of approximately 8 minutes 25
seconds (depending on the analyser type). During this time the absorbance is measured
at 28 different measuring points and the ‘Assay Type’ function on the setting sheet
defines how the selected measuring points are used to obtain an accurate result.

AU2700/AU640/AU400 Specifications:
AU2700

AU640

AU400

1600 test/hr

800 test/hr

400 test/hr

No. of probes

2

1

1

Dispensing Vol

1.6-25|al

2.0-50|il

2.0-50pl

No. of cuvettes

330

153

88

Rl+R2</= 400

Rl+R2</=500

Rl+R2</=500

Reagents

48x2

48x2

76

Bottle type/ml

15,30, 60,120,180

15,30, 60,120

15,30, 60

Measuring Capacity
Sample

Reagent
Dispensing Vol
Capacity

Table 1.3 Specifications of Olympus Analysers

31

1.5.1

Calculating Results

Reagents inherently have some optical characteristics; therefore in order to get an
accurate reading of analyte in the sample the Optical Density of the reagent must first
be calculated. This is achieved by using the reagent to test an analyte free sample - i.e.
deionised water. This is known as a ‘Reagent Blank’ and the analyser then uses the
value obtained here to eompensate for any optical contribution made by the reagent to
the final optical density of the reaction.

1.5.2

Calculation Methods

There are three main types of assay calculation each with variations on the same basic
principle.
The End Point Assay determines the optical density of the reaction mixture from the
optieal density measured at a specified photometric measuring point. The first reading
is taken against R1 only (PO). The second measuring point is taken at any stage once
the reaction is complete. The absorbance at PO is subtracted from the second measuring
point to calculate the final absorbance.

The Rate Assay measures the variation in the rate of absorbance per minute by
caleulating the average change in absorbance between each two photometric points
using the least squares method.

The Fixed Point Assay, as graphed below, determines the difference between the
optical densities at two specific positions where a reaction is taking place.
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Fig 1.6 Fixed Point Assay

AOD = Px-Py when the reaction is positive
= - (Px-Py) when the reaction is negative

where Px is the last point OD and Py is the first point OD.

1.5.3

Determination of Analyser Settings

Application of a reagent to an automated analyser requires that certain parameters,
known as settings, be assigned in order that the results obtained will be true and
accurate. The main settings to be determined are sample volume, reagent volume (both
R1 and R2) and any diluents required, wavelength, assay type and reaction time. The
adjustment of any of these parameters may affect the performance of the assay in terms
of linearity, precision and sensitivity.

The sensitivity and precision of the assay is strongly influenced by sample volume. In
general a large sample volume will provide an assay with high precision and sensitivity
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however this may lead to an increase in the effects of interferents and a reduction in
linearity.
When defining the settings for use on the analyser restrictions of specific instruments
must also be taken into account as not all analysers have the same dispensing volumes
- see Table 1.3 above.

The assay wavelength depends greatly on the reaction mechanism of the test in
question - not all wavelengths are suitable for observing certain reactions. Another
point to consider when assigning the wavelength to the assay is the potential effects of
interferents at particular wavelengths. Haemoglobin, bilirubin and lipemia may cause
spectral interference in an assay. These effects can be reduced by using a blank channel
system or by employing a bichromatic measurement.

The measuring points are determined based on the assay type and are chosen for
optimum performance of the reagent.
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2.0

Materials

2.1

Reagents

Material
104nm Latex Microparticles
102nm Latex Microparticles
102nm Latex Microparticles
96nm MPs PL-Latex Super Carboxyl
White
148nm Latex Microparticles
151nm Latex Microparticles
150nm Latex Microparticles
191nm MPs PL-Latex Super Carboxyl
White
197nm Latex Microparticles
198nm Latex Microparticles
198nm Latex Microparticles
250nm Latex Microparticles
302nm Latex Microparticles
324nm Latex Microparticles

Supplier
Seradyn
Seradyn
Seradyn
Polymer Laboratories

Product Number
100161100340
100144100240
63000392100290
6201-610

Seradyn
Seradyn
Seradyn
Polymer Laboratories

100212100340
100680100240
100195100240
6202-610

Seradyn
Seradyn
Seradyn
Seradyn
Seradyn
Seradyn

100255100240
100292100240
100238100240
100620100240
83000720100290
100340100240

Polyclonal Rabbit Anti-Human CRP
Polyclonal Goat Anti-Human CRP

Dako
Midland

Q 0329
73305

N-Hydroxy-succinimide (NHS)
N-(3-Dimethylaminopropyl)-N-ethyl
carbodiimide hydrochloride (EDAC)
Pentex Bovine Serum Albumin
Protease Free (BSA)
BCA™ Protein Assay
MLS monohydrate
3-[N-Morpholino]-2-hydroxy-propane
sulphonic acid (MOPSO)
Sodium Phosphate monobasic
Sodium Phosphate dibasic
Tris
Sodium Chloride

Fluka
Sigma

56480
E6383

Serologicals

82-045-2

Pierce Laboratories
Fluka
Sigma

23225
69889
M8389

Sigma
Sigma
Sigma
Sigma

S-2554
S-9763
T1376
S-1679

High CRP Material
Gelatin from Cold Water Fish (FSG)
VSP CRP Free Material
Dextran from Leuconostoc
Mesenteroides
SDS

Scipac
Sigma
Biocell
Sigma

P100-7B
G7041
6111-00
D5251

Sigma

Cl 344
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2.2

Apparatus

Name
PDIO Column
UV Spectrophotometer
AU400
AU640
Microplate Reader
Sonification Device
Tangential Flow Device

Supplier
Sarstedt
Kontron
Olympus
Olympus
Biotek
Branson
Spectrum Laboratories
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3.0

Methods

3.1

Preparation of Buffers

3.1.1

SOOmMMES:

106.68g MES monohydrate was diluted in 200ml of deionised water in a beaker.

The pH of the buffer was then adjusted to 6.10 using concentrated Sodium Hydroxide
solution.

The buffer was then transferred to a volumetric flask and filled to a final volume of
500ml with deionised water.

3.1.2

500mM MOPSO:

112.65g MOPSO was diluted in 200ml of deionised water in a beaker.

The pH of buffer was then adjusted to 7.4 using concentrated Sodium Hydroxide
solution.

The buffer was then transferred to a volumetric flask and filled to a final volume of
500ml with deionised water.

The working MES and MOPSO buffers were diluted from these concentrates as
required.

3.1.3 IM Tris Base:

12.1g Tris was diluted in deionised water to 100ml in a volumetric flask and mixed
using magnetic stir-bar.
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3.1.4

10%(w/w)SDS:

5.00g SDS was dissolved in 45.00g of deionised water.

3.1.5

Alkaline SDS:

50ml of IM Tris and 25ml of 10% SDS were mixed and diluted to a final volume of
250ml in a volumetric flask using deionised water.

3.1.6

10%(w/w) BSA:

lO.OOg BSA was dissolved in 90.00g of deionised water.

3.1.7

10%(w/w) FSG:

FSG was brought to RT before use.
10ml of FSG was added to a volumetric flask by weight. The solution was then brought
to 100ml in deionised water.

3.1.8

Sodium Phosphate Buffer:

a) 1.42g of Na2HP04 diluted in 50ml of deionised water in a volumetric flask
and mixed at RT.
b) 1.2g of NaH2P04 diluted in 50ml of deionised water in a volumetric flask
and mixed at RT.

The sodium phosphate buffer was prepared by titrating the 0.2M Na2HP04 against
NaH2P04 to a pH of 4.5.
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3.1.9

Borate Buffer:

9.55g Na2B4O7.10H2O was dissolved in 500ml of deionised water. 65ml of this
solution was then mixed with 35ml of 0.1 M HCl solution to yield a mixture of final pH
8.53 at 20°C.

3.1.10 Carbonate Buffer:

0.84g of NaHCOs was dissolved in 100ml of deionised water in a volumetric flask and
mixed at RT.
2.86g of Na2CO3.10H2O was dissolved in 100ml of deionised water in a volumetric
flask and mixed at RT.

The buffer was prepared by titrating hydrocarbonate solution against the carbonate
solution to yield a final carbonate buffer of pH 9.6 at 20°C.
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3.2

Development of Assay

3.2.1

Preparation of Antibody

On purchase, the antibody was in storage buffer. While appropriate for preserving the
protein this buffer may not be a suitable pH for the reaction. The presence of salts in
the buffer may also cause adverse side effects. The antibody is therefore transferred
into the working buffer before use as follows:

a) PD-10 column is washed in preparation for use by the working buffer. In all
cases this was 50mM MES unless otherwise specified. The PD-10 column is set
up using a retort stand and clamp to allow ease of use.
b) 10 collection tubes are set below the outlet of the column.
c) 2ml of antibody was pipetted into the column.
d) Immediately after this the eluate is collected in the first of the ten tubes.
e) Once the 2mls of eluate is collected 2ml of working buffer is pipetted into the
PD-10 column.
f) Repeat steps d) and e) until all ten tubes have been filled.
g) Measure all ten fractions at 280nm and pool the ones containing protein and
remeasure.
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3.2.2

Antibody Assessment

The gels and buffers used in this procedure were purchased ready-made from
Biosciences Ltd.

1. The running buffer was prepared by diluting 50ml of the 20X NuPAGE® MES
Buffer with 950ml of deionised water in a graduated cylinder. The solution was
covered with parafilm and mixed by inversion.
2. The samples of antibody were prepared to yield a final concentration of 0.5|ig
of protein per well. Samples to be measured were then prepared as follows:
Reagent

Non-Reduced Sample

Antibody Sample

25pl

NuPAGE® EDS Sample Buffer (4X)

25pl

Deionised Water

50pl

Total Volume

lOOpl

The maximum loading volume of sample is 37|il/well for the 1.5mm 10 well
gel.
3. Samples were then denatured by heating to 70°C for 3 minutes prior to use.
4. The upper chamber of the Invitrogen XCell Surelock^^ Mini-Cell was filled
with 200ml of running buffer (prepared as per no. 1 above). The buffer level
was checked to make sure it exceeded the level of the wells.
5. The wells were loaded with 20fil of sample from the preparations above.
6. Once the samples were loaded the lower chamber of the cell was then filled
with 600ml of running buffer.
7. The current applied was according to the NuPAGE® Electrophoresis settings:
Start: 100-125mA; End: 60-80mA.
8. The SDS program was run at 200V constant power for 35 minutes.
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3.2.3

Gel Staining

1. Following electrophoresis the gel was removed from the plates and placed in a
large weigh boat.
2. The gel was then washed 3 times carefully with 100ml of deionised water on an
orbital shaker to remove SDS and buffer salts, which interfere with the binding
of the dye to the protein.
3. A fixing solution of 40% methanol, 7% acetic acid and 43% deionised water
was prepared the gel was fixed in this solution for 15 minutes.
4. The gel was then washed again 3 times on an orbital shaker for 5 minutes per
wash.
5. 20ml of Coomassie Blue Solution, Gel Code® Blue Stain Reagent, was added
to a weight boat containing the gel.
6. The weigh boat was shaken gently and the protein bands were allowed to
develop over 2 hours at RT.
7. The stain was then discarded from the weigh boat and replaced with deionised
water
8. The gel was then washed again 3 times for a 3-hour period.
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3.2.4

Adsorption of Protein to Microparticles

In the initial feasibility stages all binding procedures were carried out for a final
volume of 1ml in microcentrifuge tubes.

1. The reaction was set up by pipetting samples into microcentrifuge tubes in the
following order:

50pl of 500mM MBS (to give 25mM final concentration)
Deionised Water to give 1.0ml final volume
lOOpl of 10.0% solids stock microparticles (to give 1.0% final solids)
Protein stock solution (to yield desired concentration)

2. The protein was added last and mixed very rapidly using the pipette to avoid
uneven coating of the microparticles.
3. The microcentrifuge tubes were then mixed at RT on a roller for 60 minutes.
4. Unbound protein was then removed by washing the microparticles. This was
done was spinning the particles in a centrifuge for 15 minutes at 14,000rpm.
The spinning time increased with the smaller particle size from 15 to 45
minutes. Supernatant was removed from the pellet using a pipette. 1ml of
25mM MBS was added and the pellet was resuspended using a probe sonicator
with a microtip for about 5 seconds. This washing step was carried out 3 times.
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3.2.5

BCA™ Protein Assay

The BCA™ Protein Assay is a detergent compatible formulation based on
bicinchoninic acid (BCA) for the colourimetric detection and quantitation of total
protein. This method combines the well-known reduction of Cu^^to Cu^' by protein in
an alkaline medium with the highly sensitive and selective colourimetric detection of
the cuprous cation (Cu^’) using a unique reagent containing bicinchoninic acid (Smith
1985).

Reagent A: Reagent containing sodium carbonate, sodium bicarbonate, bicinchoninic
acid and sodium tartrate in 0.1 M sodium hydroxide.
Reagent B: Reagent containing 4% cupric sulphate

1. Working reagent was prepared by mixing 50 parts of Reagent A with 1 part of
Reagent B, both of which were supplied with the Assay Kit (BCA™ Protein
Assay Kit supplied by Pierce). This solution was then incubated at 37°C for
30mins prior to use.
2. The BSA Standards were prepared by serial dilutions using the 2mg/ml BSA
solution supplied with the Assay Kit.
3. 50pl of microparticle sample to be measured (including the standards) was then
mixed with 500pl of preheated Working Reagent. This mix was then incubated
at 37°C for 30mins.
4. The samples were then placed in an ice-bath for 5 minutes to stop all reactions.
5. The microparticle samples were then spun in the centrifuge for 15mins to pellet.
6. 200pl of supernatant was then measured at 562nm using the Biotek Microplate
reader.
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3.2.6

Protein Binding Isotherm

1. Passive binding was performed in duplicate as per 3.2.4 above. Various protein
concentrations were added to the microcentrifuge tubes from 0-5mg/ml.
2. The bound protein on each microparticle was measured using the BCA Assay
as per 3.2.5 above.
3. The data was calculated against the BSA Standards as a calibration curve.

3.2.7

Blocking of Microparticle Reagents

Before immunoagglutination assays can be performed all exposed surfaces not covered
by the sensitising protein must be covered with an inert protein to prevent non-specific
interactions. Blocking was carried out by addition of a highly concentrated blocking
solution of either BSA or FSG to yield a final concentration of 0.5%.

3.2.8

One Step Covalent Coupling

1. The binding reactions were set up in inicrocentrifuge tubes in the following
order:
50|il of 500mM MBS (to give 25mM final concentration)
Deionised Water to give 1.0ml final volume
lOOpl of 10.0% solids stock microparticles (to give 1.0% final solids)
Protein stock solution (to yield desired concentration)
2. The tubes were rolled at RT for 15 minutes.
3. EDAC (1 molar excess over microparticle carboxyl concentration) was
prepared after the 15 minutes of rolling and added rapidly to the protein
solutions. The reaction mixture was mixed very rapidly after addition of EDAC.
4. The tubes were then rolled for 60 minutes at RT.
5. The tubes were spun in a centrifuge for 15 minutes until a pellet had formed.
The supernatant was then removed and the pellet was resuspended in 25mM
MES.
6. The washing step number 5 was repeated twice.
7. A BCA assay was performed as described above in order to determine how
much antibody was bound to the microparticle.
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3.2.9

Washing of Passive and Covalently Bound Microparticles

Covalently bound protein can be accurately measured by first eluting passively bound
protein with a combination of base and detergent. The technique used for this was
developed at Seradyn and removes adsorbed protein in 30 minutes. Once removed the
remaining protein on the microparticle, which can only be covalently bound, is
measured by BCA assay.

1.

1.2ml of alkaline SDS was added to 120pl of microparticle solution (covalently
bound).

2. The solution was then mixed gently and allowed to stand at RT for 30 minutes.
3. The solution was then spun in a centrifuge for 15 minutes until the
microparticles formed a pellet.
4. The supernatant was discarded and the pellet was resuspended in 500pl alkaline
SDS. This is done in order to dilute any protein-containing supernatant left on
the pellet.
5. The solution is spun again and the supernatant is discarded.
6. The protocol then calls for the pellet to be transferred immediately into BCA
working reagent. After incubation (as per procedure defined above) a colour
change was observed as expected for all protein solutions. Contrary to
expectation however was the colour change observed in the “zero” protein
microparticle mix. This colour change was shown to be due to the influence of
alkalic pH of the SDS on the BCA reagent. It was proven by the simple addition
of SDS directly to the BCA causing the colour change observed. This problem
was solved by including an extra washing step to transfer the microparticle
solution into a buffer of suitable pH.
7. The protein concentration is then measured using the BCA assay as per
procedure above, comparing both washed and unwashed microparticles, to
demonstrate passive versus covalently bound protein
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3.2.10 Two Step Covalent Coupling Initial Protocol

To obtain a more detailed view of the system an alternative more comprehensive
protocol (based on Polyscience protocol, technical data sheet 238c) was used. The
protocol is a two step one and works with an excess of EDAC in the first step and, after
removing the un-reacted EDAC, the protein is added for coupling.

1. 1 OOpl microparticle was diluted in 1.5ml of carbonate buffer pH 9.6 and spun
for 15 minutes in a centrifuge to pellet.
2. The supernatant was removed and this step (1) was repeated twice.
3. The pellet was resuspended in 1ml of 0.2M Phosphate buffer, pH 4.5, and spun
for 15 minutes in a centrifuge to pellet.
4. The supernatant was removed and this step (3) was repeated twice.
5. The pellet was then resuspended in 620|il phosphate buffer.
6. EDAC was prepared immediately before use by adding 0.1 Ig crystalline EDAC
to 5.5ml of phosphate buffer.
7. 620pl of this EDAC solution was then added drop wise to the 620|il of
microparticle solution - yielding a final EDAC concentration of approximately
0.05M.
8. The microparticle mix was then rolled at RT for 3.5 hours.
9. After rolling the particles were spun in a centrifuge until a pellet was formed.
The supernatant was removed and the pellet was resuspended in phosphate
buffer.
10 Again the particle mix was spun and the supernatant was discarded. The pellet
was then resuspended in 1ml borate buffer pH 8.5.
11. This step was repeated (step 10).
12. The particles were finally resuspended in 0.8ml of borate buffer.
13. The antibody was then added (200|il) to yield a final concentration of 50% of
saturation as determined by the protein binding isotherms.
14. The solution was then allowed to bind overnight on a roller at RT.
15. The particle solution was spun in a centrifuge for 20 minutes at 14,000rpm
until a pellet had formed.
16. The supernatant was discarded and the pellet was resuspended in 900pl of
borate buffer and 25pl of ammonium sulphide (250mM) in borate buffer.
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17. The particle solution was then spun and the resuspended in 1ml of phosphate
buffer.
18. This method was checked by BCA measurement to confirm binding of
antibody.

3.2.11 Two Step Covalent Coupling Amended Protocol

1. lOOpl of microparticle was placed into microcentrifuge tube with 900pl of
50mM MES.
2. The solution was then spun using a centrifuge at 14,000 rpm until a pellet was
formed. This took in general 15mins for larger particles and up to 45mins for
104nm particles.
3. The pellet was then resuspended in 770pl of 50mM MES. At this stage the nhydroxysuccimide (NHS) was added to a final concentration of lOOmM (230pl)
and mixed well by inversion.
4. The EDAC, which was prepared directly before use, was then added to the
NHS/MES particle solution to a final concentration of ImM and mixed rapidly
using the pipette.
5. The preparation of activated particles was then allowed to roll at RT for 30
minutes.
6. The particles were then spun to pellets and the supernatant was discarded. The
pellet was resuspended in 1ml of 50mM MES.
7. This washing step (no. 6) was repeated 3 times to ensure any excess EDAC or
NHS was removed.
8. The protein was then added to the particles to the appropriate concentration and
the binding was carried out at RT for 60 minutes on a roller.
9. The particles were then blocked using a high concentration of blocker - either
BSA ofFSG.
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3.2.12 Application of Reagent to Analyser

1. The settings originally used on Olympus analysers were as per settings for
current CRP assay -see appendix A setting sheet SOSR6x99.02.
2. The developed latex reagent was placed on-board the analyser in the R2
carousel.
3. Initially the R1 buffer developed for use with the current CRP assay was used
as the R1 buffer for this new assay.
4. The calibrators used were prepared in-house using a high spiking CRP material
and a CRP free diluent.
5. The settings were varied for optimisation. Changes were made to wavelengths,
sample volumes and reagent volumes. The influence of these changes was
observed and the final settings were chosen based on the best outcomes of these
tests.

3.2.13 Preparation of Tangential Flow Filtration System

1. The hollow fibre filter was soaked before use for 10 minutes in methanol.
2. The filter was then hooked up to the tangential flow system and the tubing and
filter were flushed with methanol for 15 minutes. This was done by circulating
approximately 20ml through the system in a continuous loop.
3. The system was then drained and water was circulated for 5 minutes.
4. This water was drained and the system was then flushed with fresh water for a
further 5 minutes.
5. The system was drained and the MES working buffer was circulated for 15
minutes to ensure that all traces of methanol and water were removed and to
ensure the filter was soaked with MES.
6. The system was then drained and considered ready for use.
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3.2.14 Covalent Coupling using Tangential Flow Filtration System - Part I.

1. The system was prepared as per 3.2.13 above.
2. The minimum working volume for use with the tangential flow system was
10ml. This was calculated based on dead volume of tubes and filter casing.
3. The microparticle solution was prepared as follows:
1ml of microparticle (10% solids) +
6.7ml MBS +
2.3ml NHS (lOOmM final concentration) +
Xml EDAC (ImM excess)
4. This solution was then loaded into the tangential flow system.
5. The system was closed, meaning no buffer was being added or removed from
the solution, and the microparticle mix was circulated in the system for 30
minutes to allow for activation of microparticles.
6. The permeate outlet tube was then opened and the latex solution was
concentrated.
7. The reservoir containing MBS was then opened and the volume of the latex
solution was brought back up to 10ml. The reservoir was closed once the
volume was 10ml and the permeate tube reopened to concentrate the particles.
8. This step (no. 7) was repeated 3 times and the particles were thus washed as the
buffer from the reservoir replaced the buffer in which the particles were stored.
9. The tubes were emptied into a container and the volume of this latex solution
was measured.
10. The volume collected was always less than 9ml. If the volume was greater than
this the solution was loaded back into the system and concentrated. This was
done by closing the reservoir allowing no more buffer to be added to the
system. The permeate was collected as usual, consequently buffer was removed
from the final solution lowering the final total volume.
11. The latex solution was removed again from the system and the volume was
measured.
12. The protein was then added to give the desired concentration in 10ml of 1%
solids microparticles. The volume of latex solution was then brought to a final
volume of 10ml using MBS.
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13. The protein-microparticle solution was then loaded back into the tangential
flow system. The system was closed so that no buffer was either added to or
taken away from the protein-microparticle solution.
14. The mix was then circulated for 60 minutes within the system in order for
binding of the protein to the particles.
15. Steps 6-9 were repeated.
16. The microparticle percentage solid was calculated based on the premise that
10ml of solution equated to 1% microparticle solids.
17. Blocking was carried out as per 3.2.7

3.2.15 Standard Curve for Assessment of Percent Solids

1. The particles were activated and washed as per 3.2.14, steps 1-8 above.
2. Instead of addition of antibody an equivalent volume of buffer was added and
the solution was rolled at RT for 60 minutes.
3. The particles that were now theoretically at 1% solids were then sonicated.
4. 0.05% Tween was then used to dilute the particles to various solid
concentrations estimated between 0.2 and 0.01% solid.
5. The particles were then measured using the Kontron Spectrophotometer at
700nm, 750nm and 800nm.
6. The straight-line graph generated by plotting microparticle concentration versus
OD was used to establish % solids in unknown samples.

3.2.16 Covalent Coupling using Tangential Flow Filtration System - Part II
1. The system was prepared as per 3.2.13 above.
2. The minimum working volume for use with the tangential flow system was
10ml. This was calculated based on dead volume of tubes and filter casing.
3. The microparticle solution was prepared as follows:

1ml of microparticle (10% solids) +
6.7ml MBS +
2.3ml NHS (lOOmM final concentration) +
Xml EDAC (ImM excess)
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4. The solution prepared was allowed to mix at RT for 30 minutes.
5. This solution was then loaded into the tangential flow system.
6. Buffer was added (MES) from the reservoir to the latex solution to bring the
final volume up to 100ml. The reservoir tap was then closed and the permeate
tap was opened. The latex solution was thus concentrated back to 10ml.
7. This step was repeated 4 times in order to ensure thorough washing of excess
EDAC or NHS from the system.
8. The volume of particles was then removed from the tangential flow system and
weighed.
9. Samples were taken from the mixture (4 x lOOpl aliquots) and diluted in 0.05%
Tween as follows: 1/10, 1/20, 1/30 & 1/40.
10. These samples were then measured in the Kontron UV Spectrophotometer
blanked against 0.05% Tween.
11. The % solid of the solution was calculated using the standard curve described
above in 3.2.15.
12 The protein was then added to give the desired concentration in 10ml based on
the exact percentage solids microparticles. The volume of latex solution was
then brought to a final volume of 10ml using MES.
13 The protein-microparticle solution was then loaded back into the tangential
flow system. The system was closed so that no buffer was either added to or
taken away from the protein-microparticle solution.
14. The mix was then circulated for 60 minutes within the system in order for
binding of the protein to the particles.
15. Steps 6-9 were repeated.
16. The microparticle percentage solid was calculated based on the premise that
10ml of solution equated to 1% microparticle solids.
17. Blocking was carried out as per 3.2.7
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3.3

Performance Verification Studies

The C-reactive protein assay was assessed for its clinical utility based on the following
performance verification studies;
Control Recovery
Linearity
Precision - 20 fold
Lowest Detectable Level
Interference Studies
Method Comparison
Prozone Tolerance
On-Board and Calibration Stability
Analytical Accuracy
Shelf-Life Stability

3.3.1

Preparation of Pools for Use in Performance Verification Studies:

All pools were made up using Gamma Depleted Human Serum as the base matrix. A
high pool of CRP, supplied by Scipac, was used to spike the Serum to required
concentrations. These concentrations were verified using a current Olympus CRP
assay. Pools were stored in aliquots at -20°C until required.

The concentration of one of the precision pools, for each assay, was at approximately
medical decision level as was the interference pool.

3.3.2

Calibration of CRP Reagent on Olympus Analysers:

Two bottles of reagent, one for Sensitive (S) and one for Normal application (N) were
placed on-board the refrigerated compartments of an Olympus analyser - AU400. The
instrument specific settings, as per Appendix A, were input. The S and N applications
have separate calibrators and these were used to calibrate the Olympus reagents. The
reagents were blanked against distilled water and controlled using Olympus Controls.
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3.3.3

Linearity Evaluation;

Linearity studies were performed in accordance with Olympus Linearity procedure
SOP R&D 003 version 8. The reference document for this procedure is NCCLA EP-6P2.

1. 40ml of defrosted Gamma Depleted Human Serum was spiked with CRP to a
concentration 10% above the linear claim. This corresponded to a high pool of
18mg/l for the HS assay and 530mg/l for the N assay.
2. The low pool consisted of unspiked Gamma Depleted Human Serum, which is
known to have a CRP level «0.05mg/l.
3. The linearity series was prepared by mixing the high and low pools in the
following ratios to yield a 15 point panel for each assay:

High Pool Content (%)

Volume of High Pool

Volume of Low Pool

(ml)

(ml)

10

1.2

10.8

20

1.2

4.8

30

1.8

4.2

40

2.4

3.6

50

3.0

3.0

60

3.6

2.4

70

4.2

1.8

80

4.8

1.2

90

5.4

0.6

100

1.0

0

4. Further dilutions at lower concentrations were then prepared using the 10%
pool as the high pool and Gamma Depleted Human Serum as the low pool:
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High Pool Content (%)

Volume of 10% Pool

Volume of Low Pool

(ml)

(ml)

0

0

6.0

0.5

0.3

5.7

1.0

0.6

5.4

2.0

1.2

4.8

5.0

3.0

3.0

5. The linearity pools were then aliquoted into 0.5ml samples and frozen at -20°C
until needed.
6. Samples were tested in quadruplicate for both Highly Sensitive and Normal
application assays. The Normal application run was controlled using Olympus
ITA controls run in duplicate and the Highly Sensitive run was controlled using
CRP HS controls also run in duplicate.
7. The results were analysed using an Olympus validated Linearity template.

3.3.4

20-fold and 10-day Precision Studies

Precision studies were carried out in accordance with Olympus Precision procedure
SOP R&D 002 version 4. The reference document for this procedure is CLSl EP5-A.

1. Low, medium and high pools were prepared by mixing Gamma Depleted
Human Serum with CRP high material to appropriate concentrations. The
analyte levels for the pools were selected in order to cover a significant portion
of the dynamic range of the assay and also based on the medical decision level
of the assay.
2.

The low, medium and high precision pools were assayed 20 fold on an
Olympus analyser. The controls for each run were assayed in duplicate. The
standard deviation (SD) and coefficient of variation (CV) at each analyte
concentration was then determined.

3. The 10-day study consisted of the low, medium and high pools being tested in
duplicate twice daily for a period of 10 days. A minimum interval of 2 hours
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was left between the two tests. In general the testing was performed morning
and evening.
4. On the first day of the 10-day precision study a fresh bottle of reagent was
placed on board each analyser and calibrated. Once the calibration and reagent
blank were confirmed to be within specification the morning portion of the
daily study was performed.
5. The frozen aliquot of each level was thawed and used for both morning and
evening assays. The runs were controlled in duplicate.
6. Results were tabulated daily using an Olympus validated Precision template.

3.3.5

Lowest Detectable Level (LDL)

1. The analyte concentration of a zero analyte sample, in this case VSP, CRP Free
Material, was determined 20-fold using both HS and N applications.
2. The run was controlled using appropriate controls run in duplicate
3. The mean, SD and LDL were calculated using an Olympus validated LDL
template.
4. The Lowest Detectable Limit is defined as follows:
LDL"= Absolute Mean + 3 Standard Deviations.

3.3.6

Interference Studies

Interference studies were carried out in accordance with Olympus Interference
procedure SOP R&D 001 version 12. The reference document for this procedure is
CLSI EP7-A.
General Procedure
1. The interferents checked were Bilirubin, Lipaemic and Haemolytic. For each
interference check performed the analyte level of serum was spiked to a CRP
concentration at the medical decision level.
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2. All Interference panels were prepared as follows:
Interferent Content (%)

Volume of High

Volume of Low Pool

Interferent Pool (ml)

(ml)

0

0

1.0

10

0.1

0.9

20

0.2

0.8

30

0.3

0.7

40

0.4

0.6

50

0.5

0.5

60

0.6

0.4

70

0.7

0.3

80

0.8

0.2

90

0.9

0.1

100

1.0

0

3. The testing was completed as soon as possible after preparation of the panel to
reduce the risk of deterioration of interferent in the solution.
4. Each dilution 0-100% was tested in quadruplicate on the three Olympus
analysers

Lipaemic Interference:
1. 300pl of 20% Intralipid was added to 5.7ml of Gamma Depleted Human
Serum. This was mixed by inversion and used as the high pool containing
lOOOmg/dl Intralipid.
2. The test pool was prepared by mixing 300pl of distilled water with 5.7ml of
Gamma Depleted Serum.
3. The panel was prepared and the testing was performed as per the general
procedure above.

Haemolytic Interference:
1. 20ml of fresh whole blood was collected in anticoagulant tubes.
2. The blood was then spun at 3000rpm on a bench top centrifuge for 15 minutes
to pack the cells.
3. The supernatant was collected and discarded.
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4. A volume of 0.9% Saline was added to the blood tube and the solution was
inverted 10 times to resuspend the cells.
5. Steps 2-4 were repeated 3 times to wash the cells.
6. On the final resuspension step purified water was used instead of Saline.
7. The cells were then frozen overnight (minimum 12 hours).
8. The cells were then thawed to RT and spun at 15,000rpm on a bench top
centrifuge for 15 minutes.
9. The supernatant collected was haemolysate material. The pellet was discarded.
10. The exact haemolysate concentration was determined by the Olympus Total
Haemoglobin assay and a stock haemolysate material was made upto lOg/dL
using 0.9% Saline.
11. 300pl of stock haemolysate material was added to 5.7ml of Gamma Depleted
Human Serum. This was mixed by inversion and used as the high pool
containing 500mg/dl of Haemoglobin.
12. The test pool was prepared by mixing 300pl of 0.9% Saline with 5.7ml of
Gamma Depleted Serum.
13. The panel was prepared and the testing was performed as per the general
procedure above.

Unconjugated (Total) Bilirubin
1. Approximately 20mg of unconjugated Bilirubin was weighed in an amber vial
and the precise weight was recorded.
2. A volume of fresh 0.1M NaOH was added, calculated as follows:
Vol NaOH (ml) = weight from Step 1 x 0.1
3. This solution once dissolved provided a lOOOmg/dl stock solution of bilirubin.
4. 240pl of the stock lOOOmg/dl solution was added to 5.7ml of Gamma Depleted
Human Serum. This was mixed by inversion and used as the high pool
containing 40mg/dl of Bilirubin.
5. The test pool was prepared by mixing 240pl of distilled water with 5.7ml of
Gamma Depleted Serum.
4. The panel was prepared and the testing was performed as per the general
procedure above.
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3.3.7

Method Comparison;

Method Comparison studies were carried out in accordance with Olympus Method
Comparison procedure SOP R&D 007 version 4. The reference document for this
procedure is CLSI EP9-A.

1. The samples varied both above and below the expected normal range for CRP.
Because it was not possible to obtain sufficient high CRP samples for the study
some patient samples were spiked with CRP High Material.
2. The samples were analysed in duplicate using the newly developed CRP
reagents versus a reference reagent. The reference assay used was the current
Olympus CRP reagent, which is traceable to IFCC Certified Reference Material
(CRM) 470.
3. Using the mean of the sample replicates a regression line was fitted to the data
and a bias plot was graphed using an Olympus validated Method Comparison
template. Data outside of the linear range of either the test or reference assay
was excluded.

3.3.8

Prozone Tolerance:

Prozone Tolerance studies were carried out in accordance with Olympus Prozone
procedure SOP R&D 008 version 6. A prozone sample is one in which the measured
level of analyte is significantly lower than the actual level present in the sample. This is
caused by the inhibition of agglutination by the presence of high concentration of
analyte.

1. The prozone pools for the Normal assay was made up using Gamma Depleted
Human Serum spiked with CRP High Material. The level of the top pool for the
assay waslOOOmg/1.
2. Prozone tolerance was tested for Normal Application only.
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3. Dilutions of the High Pool were made as follows;
CRP Content (mg/1)

4.

Volume of High Pool

Volume of Low Pool

(ml)

(ml)

0

0

1.0

100

0.1

0.9

250

0.25

0.75

500

0.5

0.5

750

0.75

0.25

1000

1.0

0

The dilutions were assayed in triplicate on the three Olympus Analysers.
Controls were run in duplicate to validate the run.

5. A dose response curve of measured concentration versus calculated
concentration for the dilutions of the prozone pools was prepared.
6. The critical point, which is the limit of prozone tolerance, was determined.

3.3.9

Shelf Life Stability

All formulations are tested in real-time to assess stability of the assay however initial
studies were carried out to measure the predicted stability.

1. The CRP reagent was stored at 37°C for 5 days.
2. Upon completion of the stress period the test reagent was stored at 2-8°C until
tested.
3. The performance check included factor assessment and control recovery and the
stressed product was tested using unstressed reagent as a control.
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4.0

Results and Discussion

4.1

Introduction to Results

The aim was to develop a reagent suitable for testing CRP both at low and at high
concentrations. The clinical range of CRP is such that two assays were required. A
Sensitive assay (S) was developed to measure CRP concentrations around the medical
decision level of lmg/1 and a normal assay (N) was developed for high concentrations
of CRP.

The results section can be separated into (i) developmental results and (ii) into
verification results.

The development results are concerned with the production of a functioning CRP
assay, and are examined in section 4.2. These results show the steps involved in
developing an assay from initial binding experiments onwards through to final
manufacture.

The verification results are those that confirm the performance of the developed assay,
and are examined in sections 4.3-4.4 below. It can be seen from these results if the CRP
assay is meeting the specifications currently required in the market for a commercial
assay. All of the verification results obtained are included as evidence of the
functioning of the CRP assay.
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4.2

Development of CRP Assay

4.2.1

Protein Assessment

Five suppliers of antibody were sourced. The purity of these antibodies was assessed
using NuPAGE® Electrophoresis system which is a neutral pH, discontinuous SDSPAGE, pre-cast polyacrylamide mini-gel system.
No. 1

No. 2

No. 3

No. 4

No. 5

Fig 4.1 Electrophoresis results for assessment of antibody purity
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The antibodies chosen to work with initially were selected based on this electrophoresis
experiment. Two antibodies were highlighted as being of superior purity - numbers 2
and 3. Antibodies number 1 and 4 are not free from serum albumin and IgM
respectively. In the case of antibody 5 there appears to be 30-40% impurities - most
likely serum albumin.
The antibodies chosen will be referred to as Antibody A and Antibody B for the
remainder of the study.
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4.2.2

Microparticle Assessment

Parking Area is a parameter that allows comparison of CM-MPs of different diameters
and titration values (meq/g). It is an area-normalised density of carboxyl groups, given
in A /COOH. There is an inverse relationship between the PA number and the MP acid
content. As the PA number decreases, the MP acid content increase. Different sizes of
particles and different parking areas were selected and passively coated. Dose response
curves were generated and particles for all future experiments were thus chosen. The
particles selected may be characterised by highest degrees of carboxylic modifications
on their surfaces. Particles with lower amount of COO- groups on the surface show
much higher tendency to colloidal non-stability when working with IgG (particularly
rabbit). Selected particles are further referred as 200nm, 150 and 100.

Fig 4.2 Dose Response Curve for similarly sized particles with different parking areas. 104nm particles,
parking area 23 A^; 96nm particles, parking area 40 A^; 102mn particles, parking area 53 A^ and 102nm
particles parking area 139 A^.

Based on the graph above, and observation of the microparticles once coated with
protein, the 104nm microparticles with the lowest PA of 23 were chosen. These were
the most colloidially stables particles. Also there was no evidence of a hook effect up
to 150mg/L of CRP making the 104nm particles a good candidate for the Normal range
assay.
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4.2.3

Binding Isotherms

In this study an adsorption isotherm is the curve that results from plotting bound
protein against added protein after performing a series of adsorptions. The protein
adsorption isotherms were performed in order to become familiar with the particleprotein behaviour. The isotherms give information about the affinity of the protein for
the particle, and the amount of protein required to saturate the microparticle surface
area. Once saturation is reached the addition of more protein does not result in efficient
binding. The microparticle saturation point (100%) was determined using the graphs
below. Following this all future binding experiments were carried out using 50%
particle saturation - this was to ensure that sufficient protein is bound for the assay
function while still allowing space on the particle for a blocking protein. Not all
microparticle sizes (100-200nm) reached 100% saturation, however based on analysis
of the graph slope showed saturation neared 100%. Consequently the 50% saturation
value was determined as an approximation.

Fig 4.3 lOOnm Binding Isotherm
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Fig 4.5 200nm Binding Isotherm
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4.2.4

Passive Binding

Once the most suitable antibodies were chosen, based on purity, and the optimum
levels for protein binding were determined from the above adsorption isotherms, the
CRP antibody was passively adsorbed to the various latex microparticles. The particles
were then tested on the Olympus analysers using basic MOPSO buffers as both diluent
for the latex and as the R1 buffer.

The passively bound microparticle reagent was tested using the same settings as per the
current Olympus Highly Sensitive assay - see Appendix A.

Fig 4.6 Passive Binding lOOnm
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Fig 4.7 Passive Binding 150nm

Fig 4.8 Passive Binding 200nm

The dose response curves generated above indicate successful binding of CRP antigen
in the samples to the CRP microparticle reagent. This is the case for all three sizes of
particles and both antibodies tested. Further testing was needed at this point before any
particular particle or antibody could be selected as being the most effective for the
assay.
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4.2.5

Active Binding

With the relative success obtained with passive coating, the particles were then
chemically bound to the antibody using both one and two-step coupling procedures as
described in Chapter 3. Before this could be attempted, the correct levels of ED AC
required for efficient binding were calculated. An EDAC titration was carried out with
concentrations ranging from 0-4mM EDAC and the EDAC concentration used was
decided based on the results.
These actively bound microparticle assays were tested at both sensitive (S) and wide
(N) application settings as per the current Olympus Assay OSR6199. See appendix A
for these settings.

Antibody A

Antibody B

Fig 4.9 Active Binding lOOnm - Highly Sensitive Application
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Antibody A

-m—

Antibody B

Fig 4.10 Active Binding lOOnm - Normal Application

Antibody A

Antibody B

Fig 4.11 Active Binding 150nm - Highly Sensitive Application
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"♦—Antibody A

Antibody B

Fig 4.12 Active Binding 150nm - Normal Application

Antibody A

Antibody B

Fig 4.13 Active Binding 200mn - Highly Sensitive Application

71

Antibody A

Antibody B

Fig 4.14 Active Binding 200nm - Normal Application

The dose response curves generated above indicate successful binding of CRP antigen
in the samples to the CRP microparticle reagent. This is the case for all three sizes of
particles and both antibodies tested. The target linear range for the highly sensitive
reagent is l-20mg/l and the target linear range for the normal application is 5 300mg/l. As we can see above, the point where the curve begins to drop off for the
highly sensitive is between 50-200mg/l depending on the size of particles - this is
known as the ‘hook’ effect and is examined in more detail in section 4.9.1 below. The
smaller particles have the highest range and it appears that the larger particles are more
sensitive at lower concentrations. From these highly sensitive graphs we can deduce
that particles of 200nm, or perhaps even larger, would provide a more sensitive assay at
low concentrations.
From examining the normal application curves it can be seen that the larger particles,
which are more sensitive at low concentrations, hook at only 200mg/l. They are
therefore less suitable for a normal application assay that needs to have an upper limit
of 300mg/l. The lOOnm particles don’t hook until after 300mg/l, thus with some
optimisation these particles provide a better option for a normal application assay.

The performance of Antibody B appears better than Antibody A in both passive and
active binding experiments. A more detailed examination of the antibodies was thus
required in order to select one for use in the CRP assay.
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4.2.6

Antibody Selection

All initial binding experiments were carried out on two different antibodies. It was not
feasible however to maintain this two streamed antibody approach for the entire assay
development. The superior antibody was chosen based on the following series of
results. The development assays were tested on the Olympus analyser AU640
alongside the current Olympus CRP microparticle enhanced assay OSR6199. The R1
buffer and R2 dilution buffer used was a basic MOPSO buffer. The assays under
development were tested using the same settings as the current CRP assay.

Sensitive Application

OSR6199

Antibody A

Antibody B

Fig 4.15 Assessment of the performance of a development CRP assay using either Antibody A or B as
compared with that of a current market CRP assay OSR6199 Sensitive Application.
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Normal Application

OSR6199

Antibody A

Antibody B

Fig 4.16 Assessment of the performance of a development CRP assay using either Antibody A or B as
compared with that of a current market CRP assay OSR6199 Normal Application.

It can be seen from the comparisons that the OSR6199 assay is superior to both
developing assays. It can also be seen however that the performance of Antibody B is
superior to that of Antibody A. These results are consistent with the binding
experiments in Sections 4.5 and 4.6. which also showed Antibody B to be superior.
Therefore Antibody B was chosen for the CRP assay.

All further assay development was carried out using Antibody B only.
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4.2.7

Optimisation of Binding Technique

Initial binding experiments were carried out on a small 1ml scale in microcentrifiige
tubes. Various methods for covalent binding were attempted and the success of binding
was tested by protein measurement using the BCA assay. The covalent binding also
added the necessity to wash the microparticles during the synthesis in order to remove
excess EDAC and NHS from the reaction. This washing step was ultimately achieved
using a tangential flow system (TFS). The TFS was used to filter the microparticle
solution using hollow fibre filters and the system later enabled the transfer of
microparticles from one buffer to another. The use of the tangential flow system forced
an increase in the scale from 1ml to 10ml synthesis. Early attempts at use of the
tangential flow system (10ml scale) yielded results that were far less successful than
those obtained on the 1ml scale - as per protocol 3.15, see Fig 4.8.1 This was
subsequently discovered to be due to unexpected loss of solid phase during the washing
step. An extra step to the synthesis was introduced whereby the exact percentage of
particles in solution was calculated prior to protein addition (see 3.17).

Fig 4.17 Comparison of Microparticle washed by Spinning method employed during small scale
synthesis (1ml) and washed by Tangential Flow Method at 10ml scale
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Fig 4.18 Comparison of Microparticle washed by Initial Tangential Flow method, where correct % solids
were unknown and Amended Tangential Flow Method where an extra step was incorporated to calculate
% solids.
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4.2.8

Total Reagent Optimisation

The size of the microparticles used, the antibody chosen, the binding efficiency of the
antibody to the microparticle, the buffers and blocking agents all play a large role in the
performance of the assay. Many optimisation experiments were carried out in order to
develop an assay achieving the desired specifications. Before any testing could be
carried out on the un-optimised reagent, settings were decided in order to apply the
reagent to the automated analysers. The settings used for all early optimisation
experiments were thus assigned as per the current Olympus CRP assay.

4.2.8.1

Particle Size

The ‘hook’ effect is characterised by the production of artificially low results from
samples that have extraordinarily high concentrations of analyte far exceeding the
upper standard of the assay concerned. The name refers to the characteristic shape of
the analytical dilution curve. This phenomenon can be seen below when we compare
microparticles of 200nm and lOOnm on the same graph. Regardless of whether highly
sensitive or normal application settings are used the 200nm microparticles have a
steeper slope at low concentrations of CRP and show evidence of the ‘hook’ at lower
CRP concentrations than that of the lOOnm microparticles.
Effect of Particle Size on Assay Performance

-♦— 100nm-------200nm

Fig 4.19 Assessment of the effects of microparticle size on the performance of the CRP assay
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From this we can conclude that larger particles are more suitable for the sensitive
assay. The small particles alternatively have less sensitivity at low concentrations but
don’t display the characteristics of the ‘hook’ effect until higher concentrations of CRP.
This makes the smaller microparticles more suitable for the wide range assay. Initially
binding experiments were carried out using even larger particles of 324nm diameter in
an effort to create an even more sensitive assay than that achieved above with the
200nm microparticles. These particles however were seen to settle in the buffering
system within hours of synthesis and thus deemed unfeasible.
200nm MPs

324nm MPs

Fig. 4.20 Evidence of settling of 324nni particles versus the unsettled 200nni
microparticles

4.2.8.2

Antibody Concentration

Protein-binding isotherms were carried out in order to establish a starting point for
assay development. Once the basic binding process was determined however some
experiments were carried out on effects of antibody concentrations on assay
performance. As can be seen below, the higher concentration of antibody provides a
more sensitive curve however this also results in a reduced range. The lower
concentration of antibody provides less sensitivity but a wider range.
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Fig 4.21 Assessment of the effects of antibody concentration on the perfonnance of the CRP assay

4.2.8.3

Blocking Agent

In order to reduce non-specific interactions any exposed surface of the MP not covered
by the sensitising protein is covered with an inert protein. This is known as blocking
the surface and is generally done by resuspending the MPs in an appropriate blocking
buffer. The choice of blocking buffer can have a strong effect on the performance of
the assay. The choice of blocking buffer also depends on the antibody chosen and type
of MP to be blocked. IgG-MPs are colloidially unstable and blocking agents stabilize
the system and are thus critical. Fish Skin Gelatin (FSG) was found by Seradyn to be a
very effective stabilizing protein. The highly charged gelatin protein with varied size
fragments is considered ideal to fit into small spaces between IgG molecules. Upon
assessment of the system the BSA blocking buffer was seen to be superior - an
example of the effect of the blocking buffers on 1 OOnm MPs can be seen below.
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Effect of Blocking Buffer on Assay Performance

E

4— BSA

FSG

Fig 4.22 Assessment of the effects of Blocking Buffer on the performance of the CRP assay

4.2.8.4

Buffer Composition

The ionic strength and pH of buffers are vitally important. Correct choice of ionic
strength and pH minimizes non-specific adsorption onto vessel walls (Selby 1999). As
mentioned previously, all binding experiments were carried out using a 50mM MES
buffer with a pH of 6.10. This was chosen based on results from experiments carried
out by Seradyn Inc., the supplier of the microparticles used in the synthesis of this
assay. The experiments carried out showed a general trend of decreasing adsorption
with increasing pH. As the pH was raised the charge on the whole system became more
negative and this charge repulsion keeps everything apart. At pH 6.10 the carboxyl
groups of the MPs are partially protonated, repulsion is minimized, and the electrostatic
attraction can act to increase protein adsorption. At higher binding pH this effect is
prevented.

In order to select a reaction buffer, RI, a series of buffers with varied pH using 200mM
MOPSO were prepared.
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Effect of pH of R1 Buffer

-♦—pH 6.0

?

pH6.5

pH 7.0

pH 8.0

Fig 4.23 Assessment of the effects of R1 pH on the performance of the CRP assay

As can been seen above little difference is observed between pH 6 and 7. At pH 8.0
there is a loss of sensitivity however the assay doesn’t hook as soon as with pH 6 and 7.
An assessment of pH between 7 and 8 was carried out in 0.2 increments. A final pH of
7.4 was chosen based on these results. Similar testing was carried out on the 25mM R2
buffer and a final pH of 7.6 was chosen as being optimum.
In order to prevent interference by variable ionic strength of biological test samples
(i.e. urine) the R1 buffer was prepared with a high ionic strength by the inclusion of
sodium chloride. EDTA at a concentration of 15mM was also included in both R1 and
R2 buffers to suppress the effect of multivalent cations.
The R1 buffer was then supplemented with the polymers Dextran and PEG to promote
agglutination.
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Fig 4.24 Assessment of the effects of Dextan on the performance of the CRP assay

Below is the effect of Dextran in greater detail between O-lOOmg/1.

Effect of Dextran

520nm 0.1% Dex

520nm 1 % Dex

x

520 no addition

Fig 4.25 Assessment of the effects of Dextan on the performance of the CRP assay - a more detailed
examination

82

Effect of PEG

■^520nm 0.1% PEG

520nm 1% PEG

520 no addition

Fig 4.26 Assessment of the effects of PEG on the performance of the CRP assay

Below is the effect of PEG in greater detail between O-lOOmg/1.
Effect of PEG

■^520nm 0.1% PEG

520nm 1% PEG

520 no addition

Fig 4.27 Assessment of the effects of PEG on the performance of the CRP assay - A more detailed
examination
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Coagulation promoters such as dextran and PEG affect different particles in the mix
with different intensity. These results can be explained by the different colloidal
stability of single microparticle populations in the R2 reagent.

No conclusion could be reached on the necessity for dextran of PEG at this stage of the
project. Therefore it was decided to reassess the need for coagulation promoters once a
more final assay composition was synthesised.

4.2.9

Reagent Composition

As mentioned previously, the larger particles were seen to have greater sensitivity at
low CRP concentrations and the smaller particles were seen to have a longer range for
high CRP concentrations. It was therefore decided to mix the particles creating a
system that could ultimately provide high sensitivity without loss of dynamic range.
The mid-size (150nm) and small (lOOnm) particles were initially mixed in a 30:70 ratio
as can be seen below

Sensitive Assay

Normal Application Assay

Fig 4.28 Mix of microparticles 150nm and lOOnm in a 30:70 ratio

From these results we can see that the sensitive assay has a wider range than required
with the hook effect occurring at lOOmg/1 CRP. The normal application was only tested
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up to 500mg/l but the slope was still increasing so the assay was not experiencing the
hook effect. This assay has the advantage of testing both normal and sensitive
application samples from one reagent bottle with the only difference being the settings.
Once the reagent was applied to the analyser for testing however it became apparent
that this was not possible with this mix of particles. The clinical sensitivity was not
sufficient for the sensitive assay. The ratio of particles for this assay was thus changed
to reflect this finding.

Based on testing of the three different particles and their individual performances two
separate mixes were prepared to test CRP. The first mix contained a 40:60 ratio of
ISOnm particles to lOOnm particles. This mix was used to test the Sensitive assay. The
40:60 ratio was chosen due to the consistent findings that the ISOnm particles were
more sensitive than the lOOnm particles. The second mix contained a 31:69 ratio of
ISOnm to lOOnm particles - a slight change from the 30:70 ratio above. This mix was
used to test the normal application. This was due to the consistent findings that the
lOOnm particles had a longer range than the larger particles.

Both sets of particles were prepared separately as detailed in the Methods section. The
particles were covalently bound and blocked with BSA. The particles were sonicated
once mixed in order to ensure homogeneity.
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4.3

Verification of the Sensitive CRP assay

The latex part of the R2 buffer was prepared and diluted in a 25mM MOPSO buffer
with pH 7.6. The R1 buffer was a 200mM MOPSO buffer of pH 7.4. Bronidox,
Sodium Azide and Proclin 300 were used as preservatives in both buffers. 2% Normal
Rabbit Serum was included in the R1 to prevent heterophilic interferences.

Various settings were tested for both applications. The settings for the Sensitive Assay
are those as per Appendix A

The calibrators were prepared using a commercial CRP material of known
concentration. The CRP material was diluted by weight in a CRP free serum pool and
the concentrations were then checked against OSR6199, the current Olympus CRP
assay. Partial value assignment was carried out on these calibrators using OSR6199.
The assigned values were established by running patient samples against the developed
assay and comparing the results of these patient samples against those obtained using
OSR6199.

Target assignment was not carried out on the controls used during verification of the
assay. This means that the targets used for the control values are those suitable for
OSR6199 only.
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4.3.1

Control Recovery Sensitive Application

ANALYZER
PARAMETER:

CRP HS

Olympus AU400

RECOVERY OF CONTROL
SERA
Control Serum/

Non -Target
Lot No

Standard
ODC0013 L1
ODC0013 L2

10
10

Overall Means/Deviations

Target

Range

Result

Deviation

(mg/L)
1.1025
1.536

(%)
-22.90
-11.72

1.31925

-16.77

(mg/L)

Min

Max

(mg/L)

1.43
1.74

1.14
1.39

1.72
2.09

1.43
2.015

(%)
0.00
15.80

1.7225

8.68

1.585

CONTROL SERA PRECISION

Target

Result Deviation

Non -Target

Target

Lot No

n

CV (%)

CV (%)

ODC0013 L1

10

2

0.99

2.12

ODC0013 L2

10

2

0.35

3.31

Control Serum

2
2
2
2
2
2

Non -Target

Target

Assigned Value (mg/I)

Factor or OD

Factor or OD

MN231

0/0

0.0205

0.015

MN231

1.28/2.2

0.0321

0.0663

Sensitive Assay

MN231

2.39/4

0.054

0.1537

Sensitive Assay

MN231

4.58 / 7.75

0.1178

0.3198

Sensitive Assay

MN231

11.57/15.5

0.3479

0.4696

Sensitive Assay

MN231

20.3/20

0.5318

0.4559

REAGENT BLANKS

Non -Target

Target

R-1

1.1043

1.1021

R-2

1.0979

1.0934

CALIBRATION FACTOR (or OD)
Calibrator

Lot No

Sensitive Assay
Sensitive Assay

Table 4.1 Control Recovery for the Sensitive CRP Assay

Above are the results in mg/1 of the current Olympus Controls for the Sensitive Assay.
These controls are target assigned based on the OSR6199 assay and must be assigned
for the new assay. The column labelled ‘non-target’ contains the results the new assay
gave for these CRP controls ODC0013 prior to target assignment of the calibrators.
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The column labelled ‘target’ contains the results provided by the new assay post
calibrator target assignment. The values for the calibrators pre and post target
assignment are also highlighted.

The assay prior to value assignment was under-recovering patient samples. This means
that a patient sample of true concentration 2 mg/1 was producing a value of
approximately 1.1 mg/1 - therefore the second point on the calibrator curve was
adjusted from 1.28mg/l to 2.2mg/l to compensate for this under - recovery. This was
the case for all calibrator set points.

Deviation from the current control targets was increased by this step however patient
sample values were more closely aligned. Patient sample results must be aligned with
the current assay on the market. Although not performed as part of this project the
controls must now be assigned new targets for the new assay.
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4.3.2

Linearity

PARAMETER:
INSTRUMENT:

CRP Sensitive Assay
Olympus AU400

High Pool Analytical Data Regressed Data Deviation from Regression Line
Content (%)
(mg/I)
(mg/I)
(mg/I)
0
-0.84
-0.35
-0.50
10
1.07
1.13
-0.06
20
2.75
2.62
0.13
30
4.12
4.10
0.02
40
5.62
5.58
0.04
50
7.24
7.06
0.18
60
8.88
8.54
0.34
70
10.35
10.02
0.33
80
11.94
11.50
0.44
90
12.89
12.98
-0.09
100
13.63
14.46
-0.84

(%)
143.08
-5.44
5.16
0.49
0.80
2.58
3.93
3.33
3.79
-0.71
-5.79

LINEARITY
Linear Regression

300

250

200

150

100

50

Fig 4.29 Linearity Test for Sensitive CRP Assay
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The specifications for the linearity for OSR6199 are +/- 12% deviation or 0.15mg/l.
The above assay meets with these specifications and has a linear range from <113.6mg/l. The initial aim had been to develop an assay from l-20mg/l. The upper end
of this linear range has not been reached. Those at high risk of heart disease, according
to the American Heart Association, have a CRP concentration between 3 and lOmg/1.
The upper tolerance of 13.6 mg/1 was therefore acceptable.

There are several ways in which linearity could be improved - for example increasing
the ratio of lOOnm particles and reducing the amount of 150nm particles. Doing this
however would have an adverse effect on the sensitivity at the low end of the assay.
The settings could also be adjusted to broaden the linear range. Less R2 could be added
for example - this would however affect the precision of the assay.
For the purpose of this study it was decided not to compromise the low-end sensitivity
or precision, as these were paramount to the functioning of an assay in a clinically
significant range.
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4.3.3

20 Fold Precision

PARAMETER:

CRP Sensitive Assay

INSTRUMENT:

AU400oa39

Replicate

Low

Medium

High

No

mg/L

mg/L

mg/L

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

1.66
1.76
1.69
1.75
1.74
1.73
1.74
1.73
1.74
1.73
1.76
1.74
1.76
1.71
1.78
1.76
1.76
1.73
1.70
1.73

6.68
6.74
6.75
6.69
6.73
6.77
6.72
6.74
6.73
6.78
6.70
6.76
6.77
6.68
6.69
6.70
6.66
6.66
6.75
6.67

11.28
11.28
11.30
11.28
11.20
11.32
11.28
11.28
11.26
11.29
11.24
11.39
11.22
11.41
11.30
11.27
11.31
11.16
11.23
11.25

MEAN
SD
CV

1.74
0.03

6.72
0.04

11.28
0.06

1.71%

0.59%

0.51%

Fig 4.30 Precision Verification for Sensitive CRP Assay

A within-run precision profile analysis was performed. This was done by determining
CRP concentrations of samples with 3 different CRP concentrations throughout the
measuring range in twenty replicates. Once the linear range was assessed it was
possible to decide on the three concentrations, spanning the range of the assay to check
precision. The low pool was chosen as being close to lmg/1. As stated by the American
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Heart Association people at low risk of heart disease have a CRP Concentration below
lmg/1. Those at medium risk of heart disease have a CRP concentration of l-3mg/l and
those at high risk have a concentration 3-lOmg/l. It was therefore imperative that the
assay be able to provide results accurately and precisely at these concentrations.
The results above show excellent precision across the entire range of the assay.

Precision Profile

CRP Concentration mg/I
OSR6199

In-House CRP

Fig 4.31 Precision Profile Analysis for Sensitive CRP Assay compared to a Commercial Assay

The precision profile above shows the newly developed CRP assay has a co-efficient of
variation (CV) below 4.5 % for all concentrations between 1 and 15mg/l. The current
CRP assay has a slightly better CV of below 2.5%. The specification for precision is
5% and both assays achieve this.
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4.3.4

Lowest Detectable Limit

PARAMETER:
INSTRUMENT:

CRP Sensitive Assay
AU400oa39

CRP Free Material
______ mg/I______

-0.01
-0.02
0.01
-0.05
-0.04
0.10
0.06
0.06
0.05
0.01
-0.03
0.04
0.02
0.00
0.07
0.05
0.04
0.01
0.01

MEAN

0.02

SD

0.040

LOWEST DETECTABLE LEVEL

0.14

mg/I

Fig 4.32 Lowest Detectable Level Verification for Sensitive CRP Assay
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The lowest detectable limit (LDL) refers to the very lowest concentration the assay can
read. The sensitive CRP assay has an LDL of 0.14mg/l - this result is not to be
confused with the lower range of the linearity of the assay. The reagent can often detect
very low results but this does not guarantee the result is an accurate one. It is possible
for instance to have an LDL of 0.05mg/l but a low-end linearity claim of lmg/1. In this
instance, although we can claim a linearity of <lmg/1 based on the linearity results
above, we cannot claim linearity below 0.14mg/l.
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4.3.5

0.00
2.20
4.00
7.75
15.50
20.00

Stability Testing Sensitive Assay
Fresh OD
0.0135
0.0621
0.1479
0.3249
0.4854
0.4772

Stress OD
0.0068
0.0567
0.1505
0.3423
0.5061
0.4863

Ff esh Vs Stress C^Aration Data

-♦—Fir esh

Stress

Fig 4.33 Calibration graph of Fresh Vs Stressed Reagent Sensitive Assay

Corf eietton Between Fresh Vs Stress Sensitive
Assay

Fig 4.34 Correlation between Fresh Vs Stressed Reagent

There is no significant change in the calibration curves generated between fresh and
stressed reagent. There is also excellent correlation between the two reagents.
Therefore Olympus assay can claim a shelf life stability of up to 13 months for the new
Sensitive assay as per Olympus R& D SOP 012.
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4.3.6

Method Comparison

PARAMETER:

CRP Sensitive Assay

TEST METHOD
REFERENCE METHOD;

CRP Sensitive Assay
OSR6199
57

No of Samples (n) =
Range of patient values

Test
Ref.

0.48
0.31

Mean patient value

Test
Ref.

5.07
5.14

Correlation Coefficient (r)
Regression Equation

12.87
13.54

0.982
Y = 0.894X + 0.477

METHOD COMPARISON

Fig 4.35 Method Comparison between OSR6199 Reference Reagent and the new Sensitive CRP assay

96

PARAMETER:

CRP Sensitive Assay

TEST METHOD:
CRP Sensitive
REFERENCE METHOD: OSR6199

Assay

BIAS PLOT

Fig 4.36 Bias plot between OSR6199 Reference Reagent and the new Sensitive CRP assay

CRP values of 57 samples from donors were tested against the new CRP Sensitive
assay and the Olympus OSR6199 reagent. Overall correlation is presented on the graph
above. The values greater than 2mg/l correlate very well with OSR6199. For values
less than 2mg/l values in the new sensitive assay are systematically overestimated in
comparison to those found in OSR6199. There are several potential reasons for the
overestimation. Firstly we do not have any patient samples of known CRP
concentration and therefore we cannot be certain that the new assay is overestimating
the results by 2mg/l. Another potential cause of the discrepancies between the two
assays could be the calibrator set points. The calibrator concentrations for OSR6199 are
0, 2.5, 10, 20, 80 and 160mg/l and the concentrations for the new assay are 0, 2.2, 4,
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7.75, 15.5 and 20mg/l. The larger range of the set points in the current Olympus assay
could have an effect on the shape of the curve. The new assay has 6 calibration set
points where the current assay has only 4.
FDA requirements state that a CRP assay to be used for a cardiac application must be
part of a clinical trial or correlated against an assay that has been part of a clinical trial.
This is not the case for this method comparison and therefore it is not possible to draw
a conclusion regarding the commercial viability of the assay. The new Sensitive assay
should be tested alongside an alternative assay such as the Dade Behring CRP assay.
Another factor to consider is matrix issues between the CRP free material used as a
diluent in the calibrators versus the real patient samples. This is more evident in the
lower concentrations than in the higher, which is where the matrix effect would be
most obvious. A possible solution to this would be to look at alternative matrixes for
the production of the calibrators. Below is a correlation between the new Sensitive
assay and the OSR6199 using CRP Free material spiked with various concentrations of
CRP across the measuring range. No overestimation is observed with these artificial
patient samples. This lends further support to the possibility of the matrix effects being
the cause of any deviation between results obtained with both assays.
Correlation Between OSR6199 and In-House
Sensitive Application using Spiked Samples only

y= 1.0001X - 0.3587

= 0.9981

OSR6199(mg/l)

Fig 4.37 Method Comparison between OSR6199 and new Sensitive CRP Assay using artificial patient
samples only
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4.3.7

Interference

Haemolytic Interference

Parameter:
Instrument:

CRP Sensitive Assay
Olympus AU400
HEMOLYSATE ANALYTICAL FINAL X 100
ADDED
RESULT
ORIGINAL
Hb, (mg/dl)
mg/I
(%)
0
0.85
100.0
50
0.91
105.9
0.87
102.4
100
0.94
150
109.5
200
0.98
114.3
250
0.97
113.8
300
0.98
114.8
350
0.97
114.0
400
1.02
119.7
1.04
450
121.8
500
1.08
126.5

HEMOLYSATE INTERFERENCE

Fig 4.38 Haemolytic Interference effects on the Sensitive CRP Assay
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Bilirubin Interference

Parameter:
Instrument:

CRP Sensitive Assay
Olympus AU400

BILIRUBIN ANALYTICAL FINAL X 100
ADDED
RESULT
ORIGINAL
(mg/dl)
mg/I
(%)
0
0.86
100.0
4
0.90
104.5
103.7
8
0.89
12
0.88
103.1
16
0.87
101.4
0.85
99.6
20
24
0.88
102.9
0.88
28
103.0
32
0.91
106.6
36
0.90
104.5
40
0.88
102.8

BILIRUBIN INTERFERENCE

Fig 4.39 Bilirubin Interference effects on the Sensitive CRP Assay
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Lipaemic Interference

Parameter:
Instrument:

CRP Sensitive Assay
Olympus AU400

INTRALIPID ANALYTICAL FINAL X 100
ORIGINAL
ADDED
RESULT
mg/I
(mg/dl)
(%)
0.87
0
100.0
0.82
100
93.8
0.82
93.4
200
300
0.81
93.3
400
0.76
87.6
500
0.73
83.1
0.72
600
82.5
700
0.67
76.5
800
0.63
72.3
900
0.61
70.2
0.54
1000
62.3

UPEMIC INTERFERENCE

Fig 4.40 Bilirubin Interference effects on the Sensitive CRP Assay

The International Federation for Clinical Chemistry (IFCC) defines interference as the
systematic error of measurement caused by a sample component, which does not, by
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itself, produce a signal in the measuring system. All factors associated with the
constituents of the sample are termed pre-analytical variables. Pre-analytical variables
can be divided into patient or specimen based issues. Patient based issues such as
smoking or incorrect sampling times should not be considered as assay interference
despite effects on analyte concentration (Selby 1999). In this study as can be seen in
graphs 4.38 - 4.40 above we studied the interference for specimen based analytical
variables of haemolysis and hyperbilirubinaemia and lipaemia.
No significant interference was observed from bilirubin with all results being below
7% deviation from the control pool. Surprisingly an elevated level of interference was
observed from both haemolytic and lipaemic interference. OSR6199, the current
Olympus CRP reagent, does not show interference above 10% for these analytes.
Interference from haemolysate was observed as being below 10% for samples up to
150mg/''dl but this increased to 26% in samples up to 500mg/dl. This interference
caused an over estimation of the samples. Lipaemic interference was observed as being
below 10% for sample up to 300mg/dl however this interference increased very
steadily up to 40% as concentrations increased to 1 OOOmg/dl. This interference caused
an under estimation of the samples. This trend can also be observed for OSR6199.
Although the interference does not exceed 10% in OSR6199, the samples are seen to
under-recover samples with greater concentrations of intralipid added.

4.3.8

Preliminary On-Board Recovery for Sensitive Application

RECOVERY
OF
CONTROL
SERA
Control
Serum
ODC0013
L1
ODC0013
L2

Day 15

Day 0
Lot
No

T arget
(mg/L)

Range
Min Max

Result
(mg/L)

Deviation
(%)

Result
(mg/L)

(%)

%
Drift
(%)

Deviation

10

1.43

1.14

1.72

1.07

-25.38

1.11

-22.52

3.84

10

1.74

1.39

2.09

1.56

-10.61

1.53

-11.88

-1.41

Table 4.2 On Board Stability for the Sensitive CRP Assay

Controls recover within specification on both days of testing. The % drift of control
recovery from Day 0 to Day 15 is below 5% therefore the reagent can now claim 15
day stability. The calibration was not performed after Day 0 therefore calibration
stability may now also be set at 15 days.
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4.4

Verification of the Normal CRP assay

4.4.1

Control Recovery of Normal Application

PARAMETER:

CRP NA

ANALYZER:

Olympus AU400

Day 0

RECOVERY OF CONTROL SERA
Control Serum/

Lot No

Standard

Range

Target

Result Deviation

Result

Deviation

(mg/L)

(%)

(mg/L)

Min

Max

(mg/L)

{%)

ODC0014

13

15

12

18

16.72

11.47

ODC0015

14

28.2

22.6

33.8

33.26

17.93

ODC0016

15

82.9

66.3

99.5

83.5

0.72

1.7225

8.68

Overall Means/Deviations

1.585

CONTROL SERA PRECISION
Lot No

n

CV (%)

ODC0014

13

2

0.42

ODC0015

14

2

0.28

ODC0016

15

2

0.62

Calibrator

Lot No

Assigned Value (mg/I)

Factor or OD

Cal NA Verification

MN252

0

0.0022

Cal NA Verification

MN252

10.24

0.0049

Cal NA Verification

MN252

38.02

0.0762

Cal NA Verification

MN252

152.97

0.3298

Cal NA Verification

MN252

294.03

0.5956

Cal NA Verification

MN252

458

0.6710

Control Serum

CV (%)

CALIBRATION FACTOR (or OD)
Factor or OD

REAGENT BLANKS
R-1

0.5555

R-2

0.5581

Table 4.3 Control Recovery for the Normal CRP Assay

The three controls tested were the current Olympus controls for OSR6199 and the
targets given above are as specified for that assay. These target values need to be target
assigned specific to the new assay in order to have a true reflection of the performance
of the assay regarding control recovery. Assessment using the OSR6199 target
concentrations however shows the new assay to be producing concentration results that
are within the defined specifications. Deviation at lower concentrations is more
pronounced that that at the higher control concentration of 82.9mg/l where the
deviation is only 0.72%. The precision (%CV) for the control recovery is below 1% for
all three concentrations.
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4.4.2

Linearity Normal Application

PARAMETER:
INSTRUMENT:

CRP Normal Application Assay
Olympus AU400

High Pool

Analytical Data

Regressed Data

Deviation from R(jgression Line

Content (%)

(mg/l)

(mg/l)

(mg/l)

0

0.44

0.00

0.44

0.5

2.74

2.79

-0.05

(%)
-1.89

1

5.21

5.58

-0.37

-6.66

2

10.87

11.15

-0.28

-2.54

5

28.14

27.88

0.25

0.90

10

55.01

55.77

-0.76

-1.37

20

109.87

111.54

-1.67

-1.50

30

166.58

167.31

-0.73

-0.44

40

224.00

223.08

0.92

0.41

50

280.04

278.85

1.19

0.43

60

338.30

334.62

3.68

1.10

70

388.03

390.39

-2.36

-0.61

80

452.89

446.16

6.73

1.51

90

494.96

501.93

-6.97

-1.39

100

522.32

557.70

-35.38

-6.34

LINEARITY

20

16

12

Fig 4.41 Linearity Evaluation of Normal Application CRP Assay

The specifications for the linearity for OSR6199 are +/- 10% deviation or 2mg/l. The
aim for the new CRP Latex Normal Application assay was to meet the specifications as
per OSR6199. The above assay has a deviation of no more than 7% and a linear range
from <l-500mg/l. The normal application assay can therefore be considered linear
within the desired specification range.
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4.4.3

Precision Normal Application

PARAMETER:

CRP Normal Application Assay

INSTRUMENT:

Olympus AU400
Low
mg/L

Medium
mg/L

High
mg/L

3.48
3.69
3.48
3.69
4.31
3.9
3.9
4.1
4.1
3.69
3.69
3.48
3.27
3.9
3.48
3.27
3.69
4.1
4.1
3.69

98.87
99.28
98.66
99.24
100.27
100.27
99.45
99.53
100.31
99.61
99.86
98.99
99.53
99.9
99.9
99.61
99.07
99.65
100.6
100.23

250.23
250.95
247.65
249.08
247
249.57
247.27
252.33
248.58
248.26
251
250.78
251.28
251.34
252.22
254.4
253.56
253
254.01
251.67

SD

3.75
0.29

99.64
0.53

250.71
2.23

CV

7.85%

0.53%

0.89%

Replicate
No

1
2

3
4
5
6
7

8

9
10
11
12

13
14
15
16
17

18
19
20
MEAN

Fig 4.42 20 fold Precision Evaluation of Normal Application CRP Assay

A within-run precision profile analysis was performed. This was done by determining
CRP concentrations of samples with 3 different CRP concentrations throughout the
measuring range in twenty replicates. Once the linear range was assessed it was
possible to decide on the three concentrations, spanning the range of the assay to check
precision. The low pool was chosen as being close to 5mg/l, which is the medical
decision level for the normal application assay. The medium and high precision pools
were chosen to reflect precision of the assay at higher concentrations within the
measuring range of the assay.
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4.4.4

Lowest Detectable Limit (LDL)

PARAMETER:
INSTRUMENT:

CRP Normal Application Assay
Olympus AU640

CRP Free Material
______ mg/I______

-0.69
1.15
0.00
0.23
0.23
0.00
0.23
-0.23
0.23
0.00
-0.23
-0.92
0.46
0.69
0.00
0.23
-0.46
0.23
0.92
0.69

LOWEST
DETECTABLE LEVEL

MEAN

0.14

SD

0.508

1.66

mg/I

Fig 4.43 20 fold Precision Evaluation of Normal Application CRP Assay

The lowest detectable limit for the normal application assay was determined as being
1.66mg/l. This result is higher than desired as the aim was to develop an assay linear
from l-480mg/l. It is not possible to claim linearity below the LDL of the assay. The
linear claim is therefore 1.66-480mg/l. The medical decision level, as mentioned
previously, is 5mg/l for the normal application assay therefore the LDL obtained is
acceptable.
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4.4.5

Method Comparison

PARAMETER:

CRP Normal Application Assay

TEST METHOD
REFERENCE METHOD:

CRP Normal Application Assay
OSR6199

No of Samples (n) =

50

Range of patient values

Test
Ref.

-0.12
-0.03

Mean patient value

Test
Ref.

102.92
101.78

Correlation Coefficient (r)

542.85
544.41

0.999

Regression Equation

Y = 1.026X-1.475

METHOD COMPARISON Artifical Spiked
Samples

100

200

300

400

500

600

RB^BRB^E METHOD (mg/I)

Fig 4.44 Method Comparison between OSR6199 Reference Reagent and the new Normal CRP assay
using artificial samples only
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Parameter:

CRP Normal Application

Test Method
Reference Method

CRP Normal Application
OSR6199

No. Samples
Range of Patient Values Test
Ref.

75
-0.12 542.85
-0.03 544.41

Mean Patient Value

72.93
68.3

Test
Ref.

Correlation Coefficient (r)
Regression Equation

0.998
Y = 1.006 + 4.258

METHOD COMPARISON True and Artifical
Patient Samples

Fig 4.45 Method Comparison between OSR6199 Reference Reagent and the new Normal CRP assay
using true patient samples and artificial spiked patient samples

The method comparison was carried out using 25 true patients samples and 50 spiked
artificial samples. The true samples were serum samples collected from donors and
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these samples were not adjusted in any way. The artificial samples were necessary in
order to cover the range of the CRP assay. The average CRP concentration of the
population is below lmg/1 in healthy individuals therefore CRP free material was
spiked in order to replicate samples of increased CRP concentrations. As can be seen
from the two method comparison graphs above (Fig. 4.44 - 4.45) there is very good
correlation between the new assay and OSR6199 when assessing spiked artificial
samples only. Once the true patient samples are introduced however this correlation is
reduced greatly. There is a systematic over estimation of results when using the new
assay versus the OSR6199 assay. This same issue was observed with the Sensitive
application assay. The most probable cause for this over-estimation is matrix effects in
the patient samples. The over-estimation in the case of the normal assay is
approximately lOmg/1 in samples below 5 mg/1. Unlike the Sensitive assay this is not
an issue that can be overcome by calibrator target assignment. The introduction of an
extra calibrator level below lOmg/1 may improve the overestimation but would not
eliminate it completely. Rather at this point a slight reformulation of the reagent would
need to be carried out. This would involve increasing the proportion of 150nm particle
in the mix and reducing the portion of 1 OOnm particles. The reason the current mix was
chosen, as discussed earlier, was to allow for maximum linear range while still
providing suitable sensitivity at low concentrations. The 150nm particles contribute
most to the signal measured by the analyser instrument at low CRP concentrations. By
increasing the portion of 150nm particles in the reagent the overall signal would be
increased at the low concentrations thus reducing the overall impact of the matrix
effect. The assay is currently measuring the matrix effect and reflecting this effect as
CRP concentration. This is not the case when the signal is higher (as in higher analyte
concentrations) as the impact of the matrix on the sample is negligible. The normal
application assay as currently formulated would not be suitable for measuring patient
samples below lOmg/1 because of the deviation owing to matrix effects. Another
possibility, one that is perhaps simpler than reformulation, would be the inclusion of an
agglutination accelerant such as PEG or Dextran in the R1 buffer. This was something
that was examined prior to reagent optimisation but at that stage was inconclusive. The
quantity to be added would need to be assessed by titration. The addition of PEG or
Dextran would have the effect of increasing the signal at low concentrations and thus
may solve the current issue.
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4.4.6

Interference Studies

Haemolytic Interference
PARAMETER:
INSTRUMENT:
HEMOLYSATE
ADDED
Hb, (mg/dl)
0
50
100
150
200
250
300
350
400
450
500

CRP Normal Application
AU400oa39
ANALYTICAL
RESULT
mg/I
14.78
14.75
14.70
14.85
14.87
14.75
14.67
14.70
14.95
14.82
14.73

FINAL X 100
ORIGINAL
(%)
100.0
99.8
99.5
100.5
100.7
99.8
99.3
99.5
101.2
100.3
99.7

HEMOLYSATE INTERFERENCE

Fig 4.46 Haemolytic Interference effects observed on the Normal CRP assay
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Bilirubin Interference:

PARAMETER:
INSTRUMENT:

CRP Normal Assay
AU400oa39

BILIRUBIN
ADDED
(mg/dl)
0
4
8
12
16
20
24
28
32
36
40

ANALYTICAL
RESULT
mg/I
15.40
15.59
15.89
15.85
15.68
15.64
15.66
15.71
15.80
15.68
15.42

FINAL X
100
ORIGINAL
(%)
100.0
101.2
103.2
102.9
101.8
101.5
101.7
102.0
102.6
101.8
100.1

BILIRUBIN INTERFERENCE

Fig 4.47 Bilirubin Interference effects observed on the Normal CRP assay
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Lipaemic Interference:

PARAMETER:
INSTRUMENT:

CRP Normal Application
AU400oa39

INTRALIPID
ADDED
(mg/dl)
0
100
200
300
400
500
600
700
800
900
1000

ANALYTICAL
RESULT
mg/I
15.33
14.90
14.73
14.36
14.26
14.48
14.36
14.28
14.33
14.46
14.46

FINAL X 100
ORIGINAL
(%)
100.0
97.1
96.0
93.6
93.0
94.5
93.7
93.2
93.5
94.3
94.3

UPEMIC INTERFERENCE

Fig 4.48 Lipaemic Interference effects observed on the Normal CRP assay

No significant interference was observed from any of the parameters tested.
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4.4.7

Stability Testing Normal Assay

CRP Cone
mg/I
0
10.24
38.02
152.97
294.03
458

Fresh
Stress
0.0044
0.0011
0.0124
0.0038
0.0521
0.0284
0.3264
0.2028
0.5950
0.4231
0.6781
0.5226
stability Test Normal Assay

-a—Fresh

Stress

Fig 4.49 Calibration graph of Fresh Vs Stressed Reagent Normal Assay

The reagent was stored at 37°C for 5 days. This has resulted in a significant change in
the assay performance. The cause of this difference is unclear without a more thorough
assessment. It would be necessary to now test the reagent at several different
temperatures (15°C and 25°C) to establish the stability of the product. The above result
indicates that the 13-month shelf life assigned to the sensitive assay cannot be assigned
to the normal application.
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4.4.8

Prozone Assessment Normal Assay

Prozone Test Normal Assay

Fig 4.50 Prozone testing Normal Assay

Based on the above graph, Fig 4.50, prozone tolerance for the normal application assay
can be set at 800mg/l. The upper linear claim for the assay is 480mg/l. The Olympus
analyser systems can be programmed to produce a G flag after results that are above
this linear range to indicate to the user the sample should be diluted and rerun for an
accurate concentration. The Olympus analysers can also be programmed with
‘prozone’ settings. These settings return a Z flag beside results above a specified
concentration - in this instance 800mg/l. This means that all results above 800mg/l will
be printed with a Z flag to indicate the value is a prozone value and must be diluted and
retested for an accurate concentration. This Olympus flagging system ensures that all
values outside of the linear range are brought to the attention of the lab analyst for
further investigation.
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4.4,9

Accuracy Assessment Normal Assay

Parameter:

CRP Normal Application

Instrument:

Olympus AU400

Control sera /

Target

Total allowable

Result 1

Result 2

Result 3

External Reference

(T)

Deviation Vo

mg/I

mg/1

mg/I

39.20

10.0

36.92

36.31

36.03

Mean

SD

Cl

36.42

0.46

0.51

IRMM

1 95% Cl 1
Control sera /
Lower limit I
External Reference
1
35.91
1
IRMM

95% Cl
Upper limit
36.93

Inaccuracy acceptable (95% probability)

(-D)
(+D)
% Deviation % Deviation
8.4

5.8

Yes

Yes

Conclusion:
(-D)

(+D)

Yes

Yes

(= Acceptable
inaccuracy)

Fig 4.51 Prozone testing Normal Assay

The Normal Application assay is accurate according to the Olympus specifications and
the total deviation is within 10%. The pool used to test the accuracy was the CRM470
sample as purchased from the Institute for Reference Materials and Measurements
(IRRM) making the normal assay traceable to this standard.
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5.0

Overall Discussion and Conclusion

CRP assays currently have two main functions - to assess a patient for (i) cardiac risk
or (ii) inflammation. Patients with CRP levels between 3-lOmg/l are considered to be at
high risk of having an ischemic episode. CRP levels can increase dramatically in the
body when suffering from inflammation or infection. On these occasions CRP
concentrations may reach up-to 1000 times the normal level of lmg/1. Two polystyrene
microparticle-enhanced assays were consequently developed in order to cover the
range of CRP concentrations in the body. One of the main reasons for developing a
particle enhanced assay that is the high refractive index provided by polystyrene. This
high refractive index greatly increases the sensitivity of the optical assay.

Five potential suppliers of antibody were selected and a purity test was performed on
the antibodies. This resulted in two antibodies being selected for further assessment (as
per fig 4.1 above).

Adsorptive binding of proteins to particles is not permanent. Various agents may cause
displacement of adsorbed proteins from the particle surface. Also, when the reagents
must be stored for prolonged times, low rates of spontaneous desorption can be a
serious problem. For commercial reasons this would make it impossible to develop an
assay unless the protein was covalently bound to the particle. Microparticles suitable
for covalent coupling of protein require the copolymerisation of functional groups onto
the microparticle surface. These functional groups must be sufficiently reactive to
under go bond formation with suitable side chains of the protein. The amino group is
the most commonly used group on the protein for coupling. Partial functional groups
that can react with protein amino groups include carboxyl, vinylbenzyl chloride,
epoxide, toysl chloride or aldehyde groups. A number of studies have documented
higher protein binding by polystyrene microparticles made with carboxylic acid
comonomers (Bale M. 1989) . It was therefore decided to use carboxyl-modified
microparticle to develop the CRP assay.

Performing binding isotherms assessed interaction between the microparticles and the
protein. The saturation point was established, beyond which the addition of more
protein did not result in efficient binding. Following this all future binding experiments
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were carried out using 50% particle saturation - this was to ensure that sufficient
protein is bound for the assay function while still allowing space on the particle for a
blocking protein. The 50% saturation point was slightly different for each particle size
but was in the range l-2mg/ml.

Microparticles were then assessed for the most appropriate diameter and number of
carboxyl groups on the surface. Microparticles with low parking areas were chosen (see
fig 4.2 above). These were the most colloidially stables particles. This increased
colloidal stability was due to the higher number of COO- groups on the surface - the
negative charges were keeping the particles repulsed. Various microparticle sizes were
examined across the range of diameters available. Larger particles were disqualified
based on instability within the buffering system (fig 4.20).

The protein was successfully adsorbed to the various particle sizes as can be seen in
figures 4.6-4.8. These initial adsorption experiments provided invaluable knowledge
about the assay system. From these early experiments it became apparent which
particles were better suited to a particular concentration range. The larger particles
were more sensitive at lower concentrations as can be seen by the steep slope and the
smaller particles were seen to be a better option for the normal application assay.
Covalent binding of the antibodies to the particles was achieved and echoed the results
regarding particle size as obtained by passive binding. Again the larger particles were
seen to have a higher degree of sensitivity while the smaller particles had a wider range
(see figures 4.9-4.14). As mentioned above the risk of desorption of the protein from
the particle surface posed too great a risk for a commercial assay therefore the reagent
was developed with covalently bound particles.

The actual method of covalent coupling was amended several times in order to enable
the scale up of the assay. Initially all experiments were carried out on a 1ml scale. The
manipulation of the reagent at these low volumes was relatively simple and the reagent
at this point was washed using a spinning method. For large-scale manufacture this
cleaning method is not feasible. It would be impossible to work with hundreds or
thousands of litres of latex reagent in this way. It was therefore imperative to find an
alternative method of preparing the reagent. The tangential flow system was thus
introduced and optimised to allow for a practical alternative to the spinning method for

117

washing the particles. The scale-up process was not entirely straightforward and again
amendments were made to the initial protocol. It was observed that the performance of
the assay was far superior when prepared by spinning rather than by tangential flow
methods (see fig 4.18). The reason for this was subsequently found to be due to a loss
of particles in the reagent and consequently to an incorrect amount of protein being
bound to the remaining particle. This was rectified by the inclusion of an extra step in
the process to allow for measurement of the percentage solids of the particles in the
mix.

Once the basic methods were established for the development of a functioning assay
the optimisation process began. The many factors, all of which play a vital role in the
performance of the assay, were assessed and the reagent was prepared accordingly.
Initially the testing was carried out using several particle sizes ranging from 100 to
324nm in diameter. The most appropriate particles were selected for each assay based
on these tests. The larger particles were observed to be more suitable for the sensitive
assay and the smaller ones for the wider range assay. The concentration of antibody
bound to the individual particles was also tested. It was noted that increased antibody
concentrations on the particles produced a more sensitive assay but also one that had a
much narrower measuring range as per fig 4.21. The antibody concentration was thus
optimised for each individual particle size used. The smaller particles of lOOnm
diameter had a final antibody concentration of approximately 0.4mg/ml, which allowed
the particles to maintain the desired wide range. The larger particles alternatively were
bound with twice as much protein as the lOOnm microparticles. The concentration on
the 150nm particles was approximately 0.8mg/ml as this provided the most sensitive
type of assay. The blocking proteins and buffer composition was also tested. The
particles were blocked using BSA (Fig 4.22 above) and the buffer pH was optimised
based on the results in Fig 4.23. Three preservatives were added to the buffers and an
external laboratory will test the efficacy of the preservatives in these buffers prior to
large-scale production.

Once the reagent was developed the performance verification studies were carried out.
These studies aim to show the functioning of the assay but also serve to highlight any
potential issues with the reagent prior to release for commercial use. The reagent was
tested at both sensitive and normal application settings. The following parameters were

examined: linearity, 20 -fold precision, LDL and stability. A method comparison was
also performed and various interferences were assessed.

The sensitive assay was observed to have a linear range from 0.14-13.6 mg/1 as
displayed in fig 4.29 above. This is below the desired range for this assay. The assay
however does cover the range as required by the FDA for use as a commercial cardiac
assay and is therefore acceptable for commercial production. The normal application
assay has a linear range from 1.66-480mg/l as per Fig 4.41 The medical decision level
of the normal assay, as required by the FDA, is 5mg/l therefore this assay is acceptable
for commercial production. The aim was to develop an assay that could measure
extremely elevated concentrations of CRP and this has been successful. This assay
compares well with CRP assays currently available on the market for example the
Roche Wide application assay which has an upper measuring range of 300mg/l (Chang
2006).

The precision was below 2% at the medical decision levels of lmg/1 for the sensitive
assay and below 8% at the medical decision level of 5mg/l for the normal assay. The
precision observed was below 1% for the medium and high CRP concentrations tested
in each assay. This compares favourably with current commercial assays produced by
Denka Seiken and Dade Behring (Vukovich 2003).

The lowest detectable limit for the sensitive assay was found to be 0.14mg/l and
1.66mg/l for the normal application assay.

Method comparison studies showed that both the sensitive and normal application
assays showed good correlation with the current Olympus assay OSR6199. There was
however significant matrix effects observed at low concentrations of each assay. The
potential solutions for the matrix effects are discussed in more detail above in sections
4.3.6 and 4.4.5 above.

There was no interference from bilirubin to the sensitive application assay however
interference from haemolysate and intralipids was observed. No interference from
bilirubin, haemolysate or intralipid was observed for the normal application assay.
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The normal application was tested for prozone tolerance and it is recommended that the
assay be marketed with prozone settings in place on the analyser. The sensitive
application was not tested for prozone. The calibration curve for the sensitive
application indicates that the assay has a low prozone tolerance of 15mg/l. This
calibration curve is displayed as an illustration of stability testing fig 4.33. The curve
can be seen to show evidence of the hook effect at 15mg/l. It was therefore decided that
prozone settings are put in place to flag all samples greater than 14.0mg/l as Z flags.
These Z flags prompt the analyst to dilute the sample and re-run to confirm the true
CRP concentration.

The desired on-board stability claim for this product is 90 days. It was not possible to
carry out this extensive test within the time frame of this project. Preliminary studies
for the sensitive application appear successful and these can be seen in table 4.2 above.
The normal application reagent must first be assessed for real-time stability before any
on-board claims can be made or verified.

In conclusion two assays for detection of CRP were developed successfully. Both
assays can measure CRP at the required medical decision levels. These assays would
have many advantages to an end user.
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I Data Check Parameters
Test Name

| CRPHS | V

I I Logic Check-1
Check Point-1
Check Point-2
Check Point-3
Decision Value-1
Decision Value-2
Decision Value-3
Limit Point T
Limit Point 2
#
§
t
*

|

<

|

[]

I I Logic Check -2
Check Point-1:
Check Point Interval:
Decision Value-1:
Decision Value-2:
Limit Point 1:
Limit Point 2:

Type: | Serum | V

n
B

User defined
For the zero calibrator saline should be used
Olympus CRP Latex calibrator Normal Set Cat. No.: ODC0027
Values set for working in mg/L

I I Logic Check -3
Check Point-1:
Check Point Interval:
Decision Value-1:
Decision Value-2:
Limit Point 1:
Limit Point 2:

New CRP Latex Reagent, AU400/AU640 Normal Serum/Plasma Application
Olympus Systsm Reagent: New CRP Latex Normal Assay
Specific Test Parameters
LIH
General
Test Name:
Sample:
Reagents:

Range

] I

| CRPN ] v
Volume
R1 Volume
R2 Volume

Wavelength:
Method:
Reaction slope:
Measuring Point 1:
Measuring Point 2:
Linearity :
No Lag Time:

2
110
110

Pri.
750
| FIXED
+
First
First

pL
pL
pL
V
V
y

12

Sec.

I

>

Dilution
Dilution
Dilution

Type: | Serum 1 y
nL
nL

0
75
75

pL

1

y

Last
Last

Operation: | Yes | V

Pre-Dilution Rate: | 1
Min OD
L I -0 1

27

Max OD

H[

First L
Last L
Dynamic Range:

-0.1
-0.1

First H
LastH

L
Correlation Factor:

0.2*

H|

480*

B
7^Ljl“1
On-board stability period:
90

%
y

2.5
2.5

0

Calibration Specific
General
ISE
Test Name:

| CRPN ] V

Calibration Type:I

6AB

|v

|

<

Formula:f

|

|

>

SPLINE

|

Type | Serum | V
|v

Counts:Process:

fcONC |v

Factor/OD-H
Point 1
Point 2
Point 3
Point 4
Point 5
Point 6
Point 7

0
10.24
38.02
152.97
294.03
458

1-Point Cal. Point:

|o

with CONC-0

Slope Check:

MB Type Factor:

V Advanced Calibration:

Calibration Stability Period

I

999

[X]v

I

I Data Check Parameters
Type: | Serum 1 v

CRPN I V

I I Logic Check-1
Check Point-1:
Check Point-2:
Check Point-3:
Decision Value-1:
Decision Value-2:
Decision Value-3:
Limit Point 1:
Limit Point 2:

I I Logic Check -2
Check Point-1:
Check Point Interval:
Decision Value-1:
Decision Value-2:
Limit Point 1:
Limit Point 2:

a
3^

I I Logic Check -3
Check Point-1:
Check Point Interval:
Decision Value-1:
Decision Value-2:
Limit Point 1:
Limit Point 2:

a

New CRP Latex, AU400/AU640 Sensitive Serum/Plasma Application
Olympus System Reagent: New CRP Latex Sensitive Assay
Specific Test Parameters
General
j LIH
| ISE
Test Name:
Sample:
Reagents;

j Range

j CRPHS j V
Volume
R1 Volume
R2 Volume

Wavelength:
Method:
Reaction slope:
Measuring Point 1:
Measuring Point 2;
Linearity :
No Lag Time:

10
75
75

Pri. 1 660
1 FIXED
First
First

<

j

1
1

pL
pL
pL

Dilution
Dilution
Dilution

V
V

Sec.

12

1

>

Type: | Serum | V

Pre-Dilution Rate:
Min OD
L I -0 1

0
0
1
1

0

Last
Last

Operation: | Yes | V

First L
Last L
Dynamic Range:

jv

27
Correlation Factor:

I

Max OD

hITT

First H
LastH

-0 1
-0.1

roH

h[

____

ao;
On-board stability period:

Calibration Specific
General
| ISE

|
CRPHS I V

Calibration Type:|

Point 1
Point 2
Point 3
Point 4
Point 5
Point 6
Point 7

j

I

<

I

6AB |v Formula:f

#
#
#
#
#
#

1-Point Cal Point:

I

>

I

Type | Serum | V

|v

SPLINE

o§
2.2
4.0
7.75
15.5
20
□ o

with CONC-0

Counts:Process:] CONC |v

Factor/OD-L
-0.1
-0.1
-0.1
-0.1
-0 1
-0.1
Slope Check:

1

+

2.5
2.5
2.5
2.5
2.5
2.5
V Advanced Calibratit

Calibration Stability Period:

MB Type Factor:

I 999

I Data Check Parameters
Test Name:

j CRPHSi V

I I Logic Check-1
Check Point-1:
Check Point-2:
Check Point-3:
Decision Value-1:
Decision Value-2:
Decision Value-3:
Limit Point 1:
Limit Point 2:

|

<

j

j

>

j

I I Logic Check -2
Check Point-1:
Check Point Intenral
Decision Value-1:
Decision Value-2:
Limit Point 1:
Limit Point 2:

Type: [~~Serum j V

a
B

I I Logic Check -3
Check Point-1;
Check Point Interval:
Decision Value-1:
Decision Value-2:
Limit Point 1:
Limit Point 2:

